

# International Union of Pharmacology. XV. Subtypes of $\gamma$ -Aminobutyric Acid<sub>A</sub> Receptors: Classification on the Basis of Subunit Structure and Receptor Function

E. A. BARNARD<sup>a</sup>, P. SKOLNICK, R. W. OLSEN, H. MOHLER, W. SIEGHART, G. BIGGIO, C. BRAESTRUP, A. N. BATESON, AND S. Z. LANGER

*Molecular Neurobiology Unit (E.A.B.), Royal Free Hospital School of Medicine, London, England; Neuroscience Discovery (P.S.), Lilly Research Laboratories, Indianapolis, Indiana; Department of Pharmacology (R.W.O.), U.C.L.A. School of Medicine, Los Angeles, California; Institute of Pharmacology (H.M.), ETH and University of Zurich, Zurich, Switzerland; Department of Biochemical Psychiatry (W.S.), University of Vienna, Vienna, Austria; Department of Experimental Biology (G.B.), University of Cagliari, Cagliari, Italy; Pharmaceutical Division (C.B.), Schering A.G., Berlin, Germany; Department of Pharmacology, University of Alberta (A.N.B.), Edmonton, Canada; Synthélabo Recherche (L.E.R.S.) (S.Z.L.), Bagnex, France*

I. Introduction	292
A. Earlier classifications of $\gamma$ -aminobutyric acid receptors	292
1. $\gamma$ -Aminobutyric acid <sub>A</sub> and $\gamma$ -aminobutyric acid <sub>B</sub> receptors	292
2. $\gamma$ -Aminobutyric acid <sub>C</sub> receptors	292
3. Benzodiazepine receptors	293
4. Excitatory $\gamma$ -aminobutyric acid <sub>A</sub> receptors	296
B. Conclusion on $\gamma$ -aminobutyric acid receptor types	298
II. Approaches to the classification of the $\gamma$ -aminobutyric acid <sub>A</sub> receptors	298
A. Transductional criteria	298
B. Operational criteria	298
C. Structural criteria	298
III. The structures of the $\gamma$ -aminobutyric acid <sub>A</sub> receptors	299
A. The repertoire of subunit types	299
B. The subunit number per receptor molecule	300
C. The subunit isoforms in one receptor	301
D. Possibilities for subunit stoichiometry	302
IV. Principles of the classification	303
A. Application of selectivities at the binding site for benzodiazepines and their functional analogs	303
1. The choice of a classification system	303
2. Benzodiazepine-responsive $\gamma$ -aminobutyric acid receptor subtypes	305
3. Notation	306
B. Advantages and possible modification of the classification	307
C. Nomenclature for the site binding benzodiazepines and modulators with similar activity	307
D. Benzodiazepine insensitivity	308
V. Chromosomal localization of $\gamma$ -aminobutyric acid <sub>A</sub> receptor genes	309
VI. Other binding sites in relation to the receptor classification	309
A. Other modulatory sites	309
B. The $\gamma$ -aminobutyric acid recognition site	309
VII. Conclusions	310
VIII. Acknowledgments	310
IX. References	310

<sup>a</sup> Address for correspondence: Professor E.A. Barnard, Molecular Neurobiology Unit, Royal Free Hospital School of Medicine, London, NW3 2PF, United Kingdom. E-mail: barnard@rfhsm.ac.uk.

## I. Introduction

This article does not aim to review in detail the properties of  $\gamma$ -aminobutyric acid<sub>A</sub> (GABA<sub>A</sub>)<sup>b</sup> receptors, because recent accounts of that topic are available. In this same journal, a review of the binding properties and pharmacology of these receptors has been published (Sieghart, 1995). Other reviews have dealt with their ion channel properties as well as their pharmacology (MacDonald and Olsen, 1994; Mohler *et al.*, 1996a,b), whereas others have concentrated on their molecular biology and protein structure (Wisden and Seeburg, 1992; Smith and Olsen, 1995; Stephenson, 1995; McKernan and Whiting, 1996). Further, two recent books have provided many short review articles on the functional, behavioral, and psychopharmacological aspects of GABA receptors (Tanaka and Bowery, 1996; Enna and Bowery, 1997) and an account of these latter aspects will not be repeated here.

Building on that background, we will consider here how our knowledge of GABA<sub>A</sub> receptor structure and function could lead to a classification system. Such a system is not immediately obvious from those previous accounts, as it probably would have been with a one-subunit receptor of the G-protein-coupled class. It is surely no accident that all the present series of NC-IUPHAR reports in *Pharmacological Reviews* on the nomenclature of individual receptor types have so far concerned G protein-coupled receptors.<sup>c</sup> Certainly the G protein-coupled receptor class covers by far the largest numbers of receptor types; it includes most of the cases in which known clinical drug applications can be related so directly to those types that they have given a great impetus to the receptor analyses. However, beyond those considerations, a major reason for the success in classification of those types must surely be the distinction which can be made therein between the subtypes of a receptor, based on the fact that each will be created by a single polypeptide with a pharmacology which is encoded solely by its own sequence. This is not to say that the classification of any of the receptors previously surveyed in this series has been entirely obvious or without complexities. Nonetheless, the problems involved are

<sup>b</sup> Abbreviations:  $\beta$ -CCE, ethyl ester of  $\beta$ -carboline 3-carboxylate;  $\beta$ -CCM, methyl ester of  $\beta$ -carboline 3-carboxylate;  $\beta$ -CCP, propyl ester of  $\beta$ -carboline 3-carboxylate; BZ, benzodiazepine; BZp, peripheral type BZ binding sites; CACA, *cis*-4-aminocrotonic acid; CNS, central nervous system; DMCM, methyl-6,7-dimethoxyl-4-ethyl- $\beta$ -carboline-3-carboxylate; DNA, deoxyribonucleic acid; GABA,  $\gamma$ -aminobutyric acid; HEK, human embryonic kidney; 5-HT<sub>3</sub>, 5-hydroxytryptamine type 3; mRNA, messenger ribonucleic acid; TM, transmembrane domain. Abbreviations of other compounds are given with their structures in fig. 2.

<sup>c</sup> A partial exception may appear to be the review on the purinoceptors (Fredholm *et al.*, 1994) but the structural basis was only clear at that time for the P<sub>1</sub> (adenosine) receptors and the P<sub>2Y</sub> (ATP) receptors, both being G protein-coupled types. Neither the subtypes nor the subunits of the transmitter-gated channel P<sub>2X</sub> receptors were known then.

generally concerned with borderline cases in which the sequence data or the discriminatory pharmacological tools were historically less satisfactory. How one longs for such a one-to-one correspondence in the case of the GABA<sub>A</sub> receptors!

The discussion here, therefore, is the first in the classification series to tackle a receptor of their class, i.e., the multisubunit, heteromeric ion channels directly activated by the transmitter. The combinatorial principle of receptor construction (to be discussed below) for these ionotropic receptors, which also is used extensively in glutamate and nicotinic acetylcholine receptors, introduces a higher order of complexity. The functional unit is not the single polypeptide, and further, the functional properties contributed by a given subunit can vary with its interactions with the particular set of subunits in each receptor molecule. This complexity renders the recognition of the structures of receptor subtypes in their natural setting extremely difficult (in fact, at present, usually unattainable). Thus, it is not possible to construct a classification comparable with the comprehensive scheme for native receptor subtypes obtained in the previous articles in this series. Instead, a provisional version is presented which relies on the wealth of sequence and functional data available on the *recombinant* GABA<sub>A</sub> receptors.

### A. Earlier Classifications of $\gamma$ -Aminobutyric Acid Receptors

1.  *$\gamma$ -Aminobutyric acid<sub>A</sub> and  $\gamma$ -aminobutyric acid<sub>B</sub> receptors.* GABA has been accepted as a neurotransmitter (in mammals and down to crustacea) for several decades. It is now evident that GABA mediates most inhibitory transmission events in the vertebrate brain. It was long clear that the fast, bicuculline-blocked response to GABA observed was caused by direct activation of an intrinsic anion channel in an entity subsequently termed the GABA<sub>A</sub> receptor. GABA<sub>B</sub> receptors were recognized later as bicuculline-insensitive, baclofen-stimulated metabotropic GABA receptors (Hill and Bowery, 1981) linked to G proteins. Confirmation by the deoxyribonucleic acid (DNA) cloning of a GABA<sub>B</sub> receptor, as a 7-transmembrane domain protein, has been accomplished recently (Kaupmann *et al.*, 1997). The complete structural and functional distinction between GABA<sub>A</sub> and GABA<sub>B</sub> receptors has a clear parallel to that between nicotinic and muscarinic acetylcholine receptors, between 5-HT<sub>3</sub> and metabotropic serotonin receptors, ionotropic and metabotropic glutamate receptors, or ionotropic P<sub>2X</sub> and G protein-coupled P<sub>2Y</sub> receptors for nucleotides.

2.  *$\gamma$ -Aminobutyric acid<sub>C</sub> receptors.* A third type of GABA receptor, insensitive to both bicuculline and baclofen, was designated GABA<sub>C</sub> (Drew *et al.*, 1984). The GABA<sub>C</sub> responses are also of the fast type associated with the opening of an anion channel; they are, however, unaffected by typical modulators of GABA<sub>A</sub> receptor

channels such as benzodiazepines and barbiturates (Sivillotti and Nistri, 1991; Bormann and Feigenspan, 1995; Johnston, 1996). Native responses of the GABA<sub>C</sub> type have occurred in retinal bipolar or horizontal cells across vertebrate species (Feigenspan *et al.*, 1993; Quian and Dowling, 1993; Lukasiewicz, 1996) and can be expressed by rat retinal messenger ribonucleic acid (mRNA) injection in the oocyte system (Polenzani *et al.*, 1991).

Although the term "GABA<sub>C</sub> receptors" still is used frequently for these bicuculline-insensitive ionotropic GABA receptors, we would argue that this terminology is no longer appropriate. The atypical GABA receptors at those retinal sites are mimicked when the recombinant  $\rho$  subunits are expressed, and  $\rho$  subunit mRNAs occur prominently in both human and rat retina (Cutting *et al.*, 1991; Enz *et al.*, 1995; Ogurusu *et al.*, 1995, 1997; Zhang *et al.*, 1995).  $\rho$  subunits are structurally part of the family of GABA<sub>A</sub> receptor subunits (Shimada *et al.*, 1992; Kusama *et al.*, 1993a,b), although their regulatory binding sites are obviously very distinctive. It would be unsatisfactory to separate these two branches of the ionotropic GABA receptor family as GABA<sub>A</sub> and GABA<sub>C</sub> receptors, with a metabotropic family, GABA<sub>B</sub>, lying between them. Moreover, if the designation of GABA<sub>C</sub> were retained, then it would be difficult to refuse the extension to GABA<sub>D</sub>, etc., types for ionotropic receptors which do not match either of the previously recognized GABA<sub>A</sub> and GABA<sub>C</sub> specifications. This would further decrease the logic of the GABA<sub>A</sub>/GABA<sub>B</sub> classification scheme. Thus, Sato *et al.* (1996) have proposed such a "GABA<sub>D</sub>" type, for an embryonic brainstem ionotropic GABA receptor that is insensitive to both GABA<sub>A</sub> and GABA<sub>B</sub> antagonists and is activated by both GABA<sub>A</sub> and GABA<sub>B</sub> agonists. Again, Perkins and Wong (1996) have suggested, based on an anomalous current evoked by GABA in hippocampal pyramidal neurons, that a "GABA<sub>D</sub>" channel may occur there with a different ionic selectivity. We therefore *recommend* that the term GABA<sub>C</sub>, as well as sequential terms for any new classes for ionotropic GABA receptors, be avoided. The  $\rho$ -containing receptors are best classified as a specialized set of the GABA<sub>A</sub> receptors, as will be shown below.

**3. Benzodiazepine receptors.** The interaction with benzodiazepines (BZ) (fig. 1) has been a major influence in studies on GABA receptors because of the long history of therapeutic application of BZs as anxiolytics, anticonvulsants, sedative-hypnotics, and muscle relaxants. Although the BZs were introduced first into clinical practice in the early 1960s, it was not until 1975 that these drugs were recognized to act by potentiating the inhibitory action of GABA in the brain (Costa *et al.*, 1975; Haefely *et al.*, 1975). The presence of high-affinity, specific binding sites for BZs in the mammalian brain was then demonstrated (Braestrup and Squires, 1977; Mohler and Okada, 1977). Converging lines of evidence established that these sites are in the same macromolecule as the GABA sites and the chloride channel and




FIG. 1. A diagrammatic representation of the spectrum of ligands with different efficacies, positive or negative, at the BZ binding site, and their allosteric actions on the GABA site (Haefely, 1989). The ligand efficacy depends on subunit composition. The evidence used was based on either whole animal responses or wild-type receptors. A similar profile would be obtained in, e.g.,  $\alpha_1\beta_n\gamma_2$  recombinants but not at some other subtypes.


that all three elements are coupled allosterically (Chang *et al.*, 1981; Olsen, 1981; Paul *et al.*, 1981; Sigel and Barnard, 1984). The term "GABA/BZ receptor" came into use for this complex (and is still encountered). Progress in this field until recently was driven by the synthesis of a vast range of BZs and BZ-like drugs, all acting at brain GABA<sub>A</sub> receptors and possessing clinical anxiolytic or sedative potencies correlated to their binding affinities there (Haefely *et al.*, 1985).

Based on the finding that all the BZs then tested displaced in a monophasic manner the binding of [<sup>3</sup>H]BZs in different brain regions, it originally was thought that there was a single class of BZ receptors. However, the subsequent availability of compounds (for structures see fig. 2) with non-BZ structure such as the triazolopyridazine CL 218872, imidazopyridines (e.g., zolpidem), and certain  $\beta$ -carbolines such as methyl-6,7-dimethoxyl-4-ethyl- $\beta$ -carboline 3-carboxylate (DMCM) or the propyl ester of  $\beta$ -carboline 3-carboxylate ( $\beta$ -CCP) (as well as 1-N-trifluoromethyl-benzodiazepines), which can displace [<sup>3</sup>H]BZ binding in a biphasic manner and possess a different affinity for BZ receptors in the cerebellum than those in the hippocampus or other brain regions, led to the concept of two BZ-receptor subtypes possessing a differential localization (Lippa *et al.*, 1981; Braestrup *et al.*, 1982; Leeb-Lundberg and Olsen, 1983; Sieghart and Schuster, 1984; Iorio *et al.*, 1984; Arbilla and Langer, 1986; Corda *et al.*, 1988). These were termed the BZ<sub>1</sub> and BZ<sub>2</sub> subtypes of the GABA/BZ receptor.


In addition to these two central BZ receptor types, diazepam binding sites with high affinity for many BZs but with pharmacological properties clearly distinct from those of the "central" BZ receptors were identified

A) CHEMICAL STRUCTURES OF BZ/ω LIGANDS


1) 1,4-benzodiazepines (and 1,5-benzodiazepines)




Diazepam




Clobazam




Brotizolam




Clotiazepam




Bretazenil




FG 8205




Ro 19-4603




Flunitrazepam




ZG-63




Imidazenil




Clonazepam




Flumazenil




Ro 15-4513




Ro 14-7437




Midazolam



Triazolam




2'-Oxoquazepam




L-655,708


2) β-carbolines




Abecarnil




β-CCM




β-CCP



β-CCE



ZK 93426




DMCM


FIG. 2. Structures of ligands discussed in the text. A, acting at the BZ site; B, C, and D acting at other sites.

## A) CHEMICAL STRUCTURES OF BZ/ω LIGANDS (continued)


## 3) Other structural types




CL 218872




CGS 8216




Ro 19-8022




CGS 20625




CGS 9895




NNC 14-0578




ICI 190622




Y-23684




U-93631




NNC 14-8198




NNC 14-0590




Zolpidem




Divaplon




Ru 33-203



Zopiclone



Suriclone



RP 60503

FIG. 2. Continued

## B) CHEMICAL STRUCTURES OF GABA AGONISTS OR ANTAGONISTS




FIG. 2. Continued

in several peripheral tissues (Braestrup and Squires, 1977). These were designated "peripheral type BZ binding sites" (BZp) (Basile and Skolnick, 1986; Verma and Snyder, 1989) and frequently became referred to as "peripheral BZ receptors." These BZp receptors can be distinguished because they can be labeled selectively (at submicromolar levels) by a non-BZ ligand, the isoquinoline carboxamide PK 11195, and (in rodents but not in some other species; Basile *et al.*, 1986) by an atypical BZ, 4'-chloro-diazepam (Ro5-4864) (Verma and Snyder, 1989), at sites that are insensitive to the antagonist BZ (fig. 1) flumazenil (Mohler and Richards, 1981).


The BZp receptors are unrelated to GABA receptors of any type, and the principal BZp type which has been identified by DNA cloning is a small protein that is associated largely with the mitochondrial membrane (Verma and Snyder, 1989). They are not relevant to the present classification scheme and we recommend that the term "BZ receptor" be dropped in relation to GABA receptors. The distinction made between central and peripheral BZ receptors will not be of value now, because BZp receptors subsequently have been found also in the brain.

Likewise, the term "GABA/BZ receptor," although useful for two decades, now may be considered obsolete, because (a) a binding site of some form for BZs is not specific to GABA<sub>A</sub> receptors, as just noted; (b) the BZ site is only one of a set of regulatory sites now known on GABA<sub>A</sub> receptors, as defined below, so it does not


uniquely define these receptors; and (c) as will be discussed below, some GABA<sub>A</sub> receptors are insensitive to BZs because of one of several distinct molecular causes. Thus "GABA/BZ receptors" is neither synonymous with "GABA<sub>A</sub> receptors" nor does it define precisely a single receptor subset. Similarly, the terms BZ<sub>1</sub> and BZ<sub>2</sub> for subtypes of the GABA<sub>A</sub> receptor no longer are recommended. As described below, evidence on recombinant subunits now indicates that there are many more than two subtypes of GABA<sub>A</sub> receptors. This is paralleled by biochemical evidence on brain GABA<sub>A</sub> receptor proteins, e.g., using photoaffinity labeling of their BZ sites by irreversible reaction (Mohler *et al.*, 1980) with [<sup>3</sup>H]flunitrazepam, which showed that multiple subunits carry BZ sites (reviewed by Olsen *et al.*, 1996). BZ<sub>2</sub>, as the term has been used in the literature, does not equate to any one molecular subtype alone.

4. *Excitatory  $\gamma$ -aminobutyric acid<sub>A</sub> receptors.* Yet another apparent distinction between sets of GABA receptors arises from observations that GABA can be an excitatory transmitter at certain loci in embryonic and early postnatal life in the mammal (reviewed by Cherubini *et al.*, 1991; Ben-Ari *et al.*, 1997). The excitatory response also may mediate the observed trophic role for GABA in nervous system development (Ben-Ari *et al.*, 1997). Another form of excitatory GABA response is seen in tonically stimulated adult hippocampal pyramidal neurons (Staley *et al.*, 1995; Perkins and Wong, 1996; Kaila *et al.*, 1997). All the evidence on these excitatory


**C) CHEMICAL STRUCTURES OF COMPOUNDS ACTING AT OTHER SITES ON GABA<sub>A</sub> RECEPTORS**




PK 9084




PK 11195




Picrotoxinin




Ro 5-4864




Propofol




Furosemide



Loreclezole



Pentobarbital



GYKI 52322

**D) BENZODIAZEPINES NOT ACTING AT GABA<sub>A</sub> RECEPTORS**

FIG. 2. Continued

receptors indicates that they are GABA-activated anion channels, in general similar to the inhibitory GABA<sub>A</sub> receptors. GABA<sub>A</sub> receptors therefore should be classified as one general type, whether their transduction is a depolarization or a hyperpolarization of the cell membrane. The subunit composition of these excitatory receptors has not been determined yet. It is possible that a different subunit composition increases the permeability of bicarbonate relative to chloride through the receptor channel, or that the subtypes involved are not necessarily different from those well known in the adult but that the chloride gradient across the cell membrane is inverted at the sites in question. Either of these situations could explain the observed excitatory GABA<sub>A</sub> receptor activity. The relative bicarbonate permeability of the channel rarely has been measured for any identified GABA<sub>A</sub> receptor subtype, but the possibility that it is increased in a particular case has been supported by Staley *et al.* (1995) and Perkins and Wong (1996). It need not be assumed that this would involve a receptor outside the range of GABA<sub>A</sub> receptor subtypes. Indeed, Kaila *et al.* (1997) have shown that activity-induced

changes in intracellular chloride and bicarbonate and extracellular potassium, along with normal GABA<sub>A</sub> receptor function, can account for the GABA-excitatory phase in the tonically stimulated adult hippocampus. Further, the intracellular chloride activity of developing neurons (of the rat nucleus basalis) has been measured using gramicidin-perforated patch recording and shows a large decrease from the immediately postnatal to the mature brain, sufficient to account for the excitatory and inhibitory responses, respectively (Akaike *et al.*, 1996). Likewise, the internal chloride concentration can be measured locally by confocal imaging based on a chloride-sensitive fluorescence, and this has shown that dendrites on some hippocampal or cortical neurons can exhibit a higher value than somatic locations (Inglefield and Schwartz-Bloom, 1996), confirming earlier suggestions of such a gradient. This also must be distinguished from subtype difference as a potential cause of the excitatory behavior of GABA<sub>A</sub> receptors on some dendrites. As further evidence for this, in the mature mammal the pituitary melanotropic cells are known to possess a very high internal chloride level, and activation of GABA<sub>A</sub>

receptors (of normal pharmacology) there also is depolarizing (Tomiko *et al.*, 1983). For all these reasons, it is unnecessary to provide a specific designation for receptors that mediate excitatory neuronal responses to GABA.

### B. Conclusion on $\gamma$ -Aminobutyric Acid Receptor Types

All the available evidence suggests that GABA receptors can be classified simply as two types, i.e., ionotropic (the GABA<sub>A</sub> receptors) and metabotropic (the GABA<sub>B</sub> receptors). The criteria for classification into subtypes will be very different for these two receptor families. The combinatorial basis of GABA<sub>A</sub> receptor structure produces a remarkable diversity of receptor subtypes and requires a new form of classification scheme. The GABA<sub>B</sub> receptors must be classified separately and will not be considered further here. Likewise, the "peripheral BZ receptors" are unrelated to any GABA receptors and will not be classified here.

## II. Approaches to the Classification of the $\gamma$ -Aminobutyric Acid<sub>A</sub> Receptors

It previously has been accepted in this series of receptor classifications (see Hoyer *et al.*, 1994) that the most fruitful comprehensive system is one in which evidence from three approaches, operational, structural, and transductional, is applied. How can these be applied here?

### A. Transductional Criteria

For an ionotropic receptor the transduction (intrinsic ion channel opening or closing) is by definition the same for all of its subtypes. The alternative intracellular pathways used in other receptor classes have no counterpart here. However, in principle subtle differences within this single transduction pathway still could occur. Thus, for two subtypes being activated by the same agonist it might be possible to measure different kinetic constants in the channel opening or closing steps, or different desensitization behaviors, or different distributions of the open and closed channel states. Such cases are known for subtypes of other transmitter-gated channels, e.g., glutamate receptors or P<sub>2X</sub> nucleotide receptors (reviewed by North and Barnard, 1997). Differences in the kinetic properties among GABA<sub>A</sub> receptor subtypes have been investigated rarely so far. In one case, Angelotti and Macdonald (1993) found that some difference in the single-channel properties could be discerned in two recombinant GABA<sub>A</sub> receptors expressed in a nonneural cell line. Likewise, expressed recombinant receptors containing the  $\alpha_6$  subunit exhibit, at least in some cases, distinctive channel properties (Ducic *et al.*, 1995). However, it may be difficult in practice to find such discriminatory differences in channel properties for many of the subtypes, as well as cumbersome to apply those in clas-

sification. Further, in the native setting it will be difficult, if not impossible, to determine whether any such difference instead is not caused either by some intracellular secondary reaction (e.g., a phosphorylation) or by the availability of a native modulator. Therefore, we will not consider transductional criteria for classifying these receptors.

### B. Operational Criteria

Selective antagonists have been the most powerful operational tools for discriminating subtypes in other receptor classes (Kenakin *et al.*, 1992). However, for the GABA<sub>A</sub> receptors, antagonists at the GABA site generally produce convulsions *in vivo*. Hence, therapeutic potential is limited and systematic exploration of antagonists has not been developed. A few compounds unrelated to GABA, such as certain arylaminopyridazines and cognate compounds (Heaulme *et al.*, 1987; Melikian *et al.*, 1992), have been developed as potent antagonists at GABA<sub>A</sub> receptors generally. Olsen *et al.* (1990) have shown that the binding of such compounds can discriminate between some subtypes in the brain; their functional study to identify selective actions on recombinant subtypes could be rewarding.

GABA<sub>A</sub> receptors are endowed with a variety of modulatory sites for which ligands have been found that can allosterically control the activation by GABA and/or the opening of the anion channel. With the possible exception of the N-methyl-D-aspartate subclass of glutamate receptors (another family of heteromeric ligand-gated ion channels ubiquitous in the brain), the number of different regulatory sites is greater than for any other receptor type. Modulatory sites offer the potential for discriminating among receptor subtypes, namely by the discovery or the design of agents that can act at these sites but can recognize differences in a given site as it occurs in different subunit combinations. Thus far, this possibility has been realized to some extent with the site at which BZ and molecules with BZ-like activity bind, as we shall see. Other established modulatory sites, which can exist on these receptors and which might be used thus include those for barbiturates, neuro-steroids, propofol, certain other anesthetics, furosemide, zinc, picrotoxin, and some other channel blockers, loreclezole, substituted pyrazinones, and dihydro-imidazoquinoxalines. Those compounds and the evidence of their interaction with GABA<sub>A</sub> receptors are reviewed by Sieghart (1995), Im *et al.* (1993a,b), Wafford *et al.* (1994), and Korpi *et al.* (1995). Only occasional clues to subunit selectivity have been obtained for any of the latter sites.

### C. Structural Criteria

The multisubunit compositions of the GABA<sub>A</sub> receptors, which create the subtypes, are of primary importance in their classification. In practice, it is not a straightforward task to use the subunit sequences and the subunit assemblies as the primary basis of a classi-



fication, a topic which now requires a fuller discussion below.

### III. The Structures of the $\gamma$ -Aminobutyric Acid<sub>A</sub> Receptors

#### A. The Repertoire of Subunit Types

Cloning from cDNA libraries or genomically so far has generated 19 related GABA<sub>A</sub> receptor subunits in mammals, which are each encoded by different genes. These now comprise 6 $\alpha$ , 4 $\beta$ , 3 $\gamma$ , 1 $\delta$ , 1 $\epsilon$ , 1 $\pi$ , and 3 $\rho$  mammalian types [for references see Burt and Kamatchi, 1991; plus ( $\epsilon$ ) Davies *et al.*, 1997 and Whiting *et al.*, 1997; ( $\pi$ ) Heblom and Kirkness, 1997; ( $\rho_{1-3}$ ), see Section I.A.2.; for database accession numbers see fig. 3]. These polypeptides are all ~50,000 daltons in size, and each carries four putative transmembrane hydrophobic segments (TM1–4). Figure 3 illustrates the seven different sequence families into which these fall structurally and their relationships. A mammalian counterpart of the avian  $\gamma_4$  subunit (Harvey *et al.*, 1993) has not yet been isolated by cDNA cloning and so is not included here. However, the  $\beta_4$  subunit gene, likewise discovered in the chicken (Bateson *et al.*, 1991), has been shown more recently in humans (Levin *et al.*, 1996).

This heterogeneity is increased by alternative exon splicing of the pre-mRNA, which generates two forms of the  $\gamma_2$  subunit from one gene (Whiting *et al.*, 1990; Kofuji *et al.*, 1991), which can be distributed differently in the brain (Glencorse *et al.*, 1992). Two such forms are also known for the  $\beta_2$  and  $\beta_4$  subunits (Bateson *et al.*, 1991; Harvey *et al.*, 1994). In each case, the longer and shorter products were designated “L” and “S,” and differ by some form or other of a short peptide in the long intracellular loop between TM3 and TM4. Splicing also occurs to express two alternative forms of exon-1 of the  $\beta_3$  subunit (Kirkness and Fraser, 1993). Three potential forms of the  $\alpha_5$  subunit mRNA also exist (Kim *et al.*, 1997) but with unchanged protein sequence. Another product of alternative splicing deletes a short sequence at the N-terminus of the  $\alpha_6$  subunit (Korpi *et al.*, 1994), although this abolishes the functional receptor activity in all the combinations tested so far. Therefore, in assessing possible combinations of subunit types (other than  $\rho$ ) to form a GABA<sub>A</sub> receptor, we must consider in a given mammalian species, including the splice variants, at least 7  $\alpha$  forms, 7  $\beta$  forms, 4  $\gamma$  forms, 1  $\delta$ , 1  $\pi$ , and 1  $\epsilon$  form. The recently discovered  $\epsilon$  and  $\pi$  subunits in each case can combine with  $\alpha$  and  $\beta$  subunits to form a functional, BZ-insensitive receptor (Davies *et al.*, 1997; Heblom and Kirkness, 1997; Whiting *et al.*, 1997). The  $\pi$  subunit has been detected clearly so far only in certain peripheral tissues (Heblom and Kirkness, 1997), and its range of combinations has not been defined yet. The GABA<sub>A</sub> receptors in the central nervous system (CNS) are formed, on present knowledge, by combinations of both  $\alpha$  and  $\beta$  subunits with one or more of the  $\gamma$ ,  $\delta$  or  $\epsilon$




FIG. 3. Dendrogram depicting the relatedness of amino acid sequences between GABA<sub>A</sub> receptor subunits. Amino acid sequences were retrieved from the SWISS-PROT or NCBI databases. Most GABA<sub>A</sub> receptor sequences are available from the rat and so were used for the analysis, except for the  $\beta_4$  and  $\epsilon$  subunits. The chicken  $\beta_4$  subunit sequence was incorporated because the human homologue has been identified recently (Levin *et al.*, 1996), although only a partial human sequence has yet been published. Similarly, the human  $\epsilon$  subunit has been identified (Davies *et al.*, 1997), but the rat sequence has yet to be published. Thus, accession numbers of GABA<sub>A</sub> receptor subunit sequences used were:  $\alpha_1$ , P18504;  $\alpha_2$ , P23576;  $\alpha_3$ , P20236;  $\alpha_4$ , P28471;  $\alpha_5$ , P19969;  $\alpha_6$ , P30191;  $\beta_1$ , P15431;  $\beta_2$ , P15432;  $\beta_3$ , P15433;  $\delta$ , P18506;  $\epsilon$ , U66661;  $\gamma_1$ , P23574;  $\gamma_2$ , P18508;  $\gamma_3$ , P28473;  $\pi$ , U95368;  $\rho_1$ , P50572;  $\rho_2$ , P47742 and  $\rho_3$ , P50573. Outgroup sequences (see below) were all from the rat: nicotinic acetylcholine receptor  $\delta$  (nAChR  $\delta$ ), P25110; nicotinic acetylcholine receptor  $\delta$ , P12389; and 5-hydroxytryptamine type 3 receptor, P35563. The predicted signal-peptide cleavage sites of all subunits were determined by the method of Nielsen *et al.* (1997). These did not always correspond to those previously indicated in the corresponding database entries and in such cases the newly determined cleavage sites were taken to be the more accurate. These were (signal peptide length in parentheses):  $\alpha_5$  (25),  $\beta_3$  (25),  $\delta$  (21), and  $\rho_3$  (25). A multiple alignment of the predicted mature peptides and the consequent phylogenetic tree descriptive file were created using CLUSTAL W version 1.7 (Thompson *et al.*, 1994) under the default parameters. NJPLOT (Perriere and Gouy, 1996) was used to generate the graphic output of the gene tree. The branch root was determined by including in the analysis sequences of two non-GABA<sub>A</sub> receptor subunits from the same superfamily (Barnard, 1996b). Shown in this figure is the tree generated from the rat nicotinic acetylcholine receptor  $\delta$  subunit and the 5-hydroxytryptamine type 3 (5HT<sub>3</sub>) receptor subunit as outgroup representatives. No significant differences were found when either of these were substituted with the rat nicotinic acetylcholine receptor  $\alpha_2$  subunit sequence. The sum of the horizontal branch lengths connecting any two sequences represents the fractional divergence in their amino acid sequence, the scale bar corresponding to 10% sequence divergence. Vertical branches connecting groups are presented only for clarity, and their lengths do not infer differences between separate sequences, or groups of sequences, on the tree.

subunit types (or possibly, exceptionally, of  $\alpha$  and  $\beta$  types alone). In addition there are three known  $\rho$  subunits that occur in the retina:  $\rho_1$  (Cutting *et al.*, 1991);  $\rho_2$

(Cutting *et al.*, 1992; Kusama *et al.*, 1993b);  $\rho_3$  (Ogurusu and Shingai, 1996; Shingai *et al.*, 1996). In co-expressions, evidence was not obtained to show that a  $\rho$  subunit can participate in combinations with the aforementioned  $\alpha$ ,  $\beta$ , or  $\gamma$  types (Shimada *et al.*, 1992; Kusama *et al.*, 1993a), although more recently a  $\rho_1\gamma_2$  heteromer forming in heterologous expression was suggested (Pan *et al.*, 1997). In the rat retina, however, a recent study by immunofluorescence microscopy showed punctate localizations of non- $\rho$  GABA<sub>A</sub> receptors and of  $\rho$ -containing receptors, which occur at different synapses and do not overlap (Koulen *et al.*, 1998). Hence, a pool of at least 20 subunit types may be used in forming combinatorially the CNS GABA<sub>A</sub> receptors, plus at least 3  $\rho$  subunit types which assemble in a restricted manner.

### B. The Subunit Number per Receptor Molecule

To understand the construction of GABA<sub>A</sub> receptor subtypes from this repertoire of subunits, it is necessary first to establish the total number of subunits in each receptor molecule, then to know whether this number is constant for all the native compositions, and finally to know the stoichiometry of the subunit types within that number. Regarding the number of subunits per receptor, the suggestion often has been made that this will be the same (five subunits) as for another transmitter-gated ion channel where the composition has been established unequivocally. Thus, the GABA<sub>A</sub> receptor subunits share a low but definite (~25%) amino acid sequence homology with the subunits of the nicotinic acetylcholine receptors, both being in the same superfamily of the transmitter-gated ion channels (Schofield *et al.*, 1987; Barnard, 1996b). The muscle type of that receptor occurs in *Torpedo* electric organ at such a high density in large postsynaptic membrane sheets that it is possible to prepare membranes containing a surface lattice of the receptors, from which a low-resolution three-dimensional structure of the molecule could be obtained by electron optical diffraction techniques (Toyoshima and Unwin, 1988; Unwin, 1993). Those studies clearly showed that the muscle type nicotinic receptor is pentameric, with the ion channel located in the center of a rosette formed by five homologous subunits (with the stoichiometry  $\alpha_2\beta\gamma\delta$ ).

For the GABA<sub>A</sub> receptors, the situation is necessarily more complex, because the unique situation in the *Torpedo* postsynaptic membranes does not recur in the mammalian CNS and because there are many types of subunits involved, in varying combinations, in the receptor population. It is preferable, therefore, to use the natural GABA<sub>A</sub> receptor population from the brain rather than a selected recombinant composition expressed in a nonneural cell, which may or may not be representative of the native population; further, when direct analyses are made on the latter, these will not be limited by an assumption of the subunit classes to be taken as co-assembling. Using purified GABA<sub>A</sub> recep-

tors from pig brain cortex and image analysis in the electron microscope, dispersed single receptor molecules can be visualized and analyzed (fig. 4). This method yields a power spectrum for each particle with a peak at its dominant symmetry. Figure 4 illustrates that this symmetry is five-fold, over the population of particles analyzed (Nayeem *et al.*, 1994). Further, the negatively stained images obtained for all the receptor particles indicated a central pore in the pentameric rosette. These data correspond to the images observed with negatively stained *Torpedo* receptor particles, because of a central channel in the membrane enclosed within the pentameric receptor in the latter case (Toyoshima and Unwin, 1988). The particles isolated from brain will comprise a variety of GABA<sub>A</sub> receptor subtypes. These data show that at least the majority of those receptors are pentameric; a deviating small minority with an atypical subunit number would not be distinguished from the experimental noise. Independent evidence to support the pentameric structure has been obtained in several ways. Hydrodynamic estimates of the size of GABA<sub>A</sub> receptors, either native (Mamalaki *et al.*, 1989) or  $\alpha_1\beta_3\gamma_2$  recombinants (Tretter *et al.*, 1997), in solution are consistent with the pentameric molecular weight. Further, the integral ratios of the subunits combined in several forms of functional recombinant receptors, as determined by diverse methods, fit best in each case with a subunit total of five (Im *et al.*, 1995; Chang *et al.*, 1996; Tretter *et al.*, 1997). For parallel evidence, a method similar to that of Nayeem *et al.* (1994) has been used for the native 5HT<sub>3</sub> receptors by Boess *et al.* (1995) and there is supporting evidence by other methods for the neuronal nicotinic receptors and the glycine receptor (reviewed by Barnard,




FIG. 4. Evidence for the pentameric structure of native GABA<sub>A</sub> receptors. The electron microscopic images of a population of pure GABA<sub>A</sub> receptor molecules analyzed to yield dominant symmetry for each particle were used in plotting the histogram (for details see Nayeem *et al.*, 1994). Particles with only one-fold apparent symmetry, which is trivial, were rejected. The form of the distribution seen around the peak at five-fold symmetry is consistent with 100% being pentameric, because the apparent spread to some lower symmetries can be caused by tilted particles. The distribution shown was confirmed on a large number of the particles (from Nayeem *et al.*, 1994; E. A. Barnard, personal communication).

1996b), all of these being in the same superfamily and all being deduced to be pentameric. In view of this concurrence with other receptors in the same superfamily, it is presumed that the pentameric structure that has been observed, within experimental error, for GABA<sub>A</sub> receptors holds for at least the great majority of that receptor type.

It can be concluded that the repertoire of (at least) 24 mammalian subunit isoforms described above is drawn on to a total of 5 for each receptor molecule. Evidence discussed below will show that in most (but not all) GABA<sub>A</sub> receptors  $\alpha$ ,  $\beta$ , and  $\gamma$  subunits co-exist in one molecule, and that yet other combinations exist accommodating in special ways the other subunit types,  $\delta$ ,  $\epsilon$ ,  $\pi$ , and (separately)  $\rho$ . It is assumed that the  $\rho$ -containing receptors are also pentameric, but this question has not been studied as yet.

### C. The Subunit Isoforms in One Receptor

The majority of GABA<sub>A</sub> receptors contain, as noted,  $\alpha$ ,  $\beta$ , and  $\gamma$  subunits, whereas the total number of subunits per receptor is five (fig. 4). Hence the receptors in this set can have at least one of three general compositions:  $2\alpha.2\beta.\gamma$ ;  $2\alpha.\beta.2\gamma$ ;  $\alpha.2\beta.2\gamma$ . Here, a notation is introduced in which the numeral represents the number of molecules of a given subunit class ( $\alpha$ ,  $\beta$ , etc.) present in one receptor molecule and not the isoform identity within that class; separating points are then used, and are absent when the stoichiometry is not being indicated. Such additional cases as  $3\alpha.\beta.\gamma$  and  $\alpha.\beta.3\gamma$  are theoretically possible, but measurements of an electrophysiological property determined quantitatively by the number of tagged recombinant subunits of each type forming the channel (Backus *et al.*, 1993; Chang *et al.*, 1996), in the cases of co-expression of the  $\alpha_3\beta_2\gamma_2$  or  $\alpha_1\beta_2\gamma_2$  subunits, have excluded (at least in those cases) the presence of three of any of those types in one receptor molecule. The next logical step in enumerating the potential combinations of subunits, therefore, is to ask whether two isoforms of  $\alpha$  or of  $\beta$  or of  $\gamma$  can occur in one receptor molecule, e.g., to produce compositions of the type  $(\alpha_1\alpha_2).2\beta.\gamma$ .

In the  $\alpha$  subunits, there is a variety of evidence for such a co-occurrence of isoforms in a minority of GABA<sub>A</sub> receptors. This evidence has come first from co-precipitation of a second  $\alpha$  isoform when a brain-derived population of GABA<sub>A</sub> receptors is treated with an antibody specific for a first  $\alpha$  isoform. Receptors containing at least the pairs  $\alpha_1\alpha_2$ ,  $\alpha_1\alpha_3$ ,  $\alpha_1\alpha_5$ ,  $\alpha_2\alpha_3$ , and  $\alpha_3\alpha_5$  have been detected thus (each in a minority, with the majority of receptors in the population containing a single  $\alpha$  isoform) (Duggan *et al.*, 1991; Luddens *et al.*, 1991; Zezula and Sieghart, 1991; Endo and Olsen, 1993; Mertens *et al.*, 1993; Pollard *et al.*, 1993; Khan *et al.*, 1996; McKernan and Whiting, 1996). Further, for the  $\alpha_6$  subunit that occurs (in the mature brain) only in the cerebellar granule cells (Laurie *et al.*, 1992; Thompson *et al.*, 1992) and

in the similar granule cells of the cochlear nucleus (Varecka *et al.*, 1994), antibody reactivities show  $\alpha_1$  and  $\alpha_6$  co-occurring in one cerebellar receptor (Pollard *et al.*, 1995; Khan *et al.*, 1996), although not for all the  $\alpha_6$  subunits there. For the  $\gamma$  subunits, the similar use of isoform-specific antibodies has, on brain extracts or purified receptor preparations, shown evidence for the co-occurrence of  $\gamma_2$  with  $\gamma_3$  and also of  $\gamma_{2L}$  with  $\gamma_{2S}$  (Khan *et al.*, 1994a,b; Quirk *et al.*, 1994a).

A second method for investigation of possible co-occurrence of particular isoforms is the application of isoform-specific antibodies in situ, i.e., in light or electron microscopic studies (table 1). Thus, by confocal laser microscopy with double or triple immunofluorescent staining, Fritschy *et al.* (1992) and Mohler *et al.* (1996a) have found that certain  $\alpha$  pairs were co-localized on the membranes of various neurons (table 2). Co-localization of  $\alpha_1$  and  $\alpha_6$  subunits in single synapses of rat cerebellar granule cells also has been demonstrated by double-antibody labeling in postembedding electron microscopy (Nusser *et al.*, 1996), although when used in a freeze-fracture method on such cells in culture a co-localization of  $\alpha_1$  and  $\alpha_6$  was not seen (Caruncho and Costa, 1994). Third, some electrophysiological properties of a recombinant  $\alpha\beta\gamma$  assembly containing two isoforms of  $\alpha$  can be distinct from those with either isoform separately, demonstrated with  $\alpha_1\alpha_3$  or  $\alpha_1\alpha_5$  pairings (Ebert *et al.*, 1994; Verdoorn, 1994).

Further, the  $\delta$  subunit often has been found to replace  $\gamma$  subunits: Quirk *et al.* (1995) found that  $\delta$  and  $\gamma$  are completely separable by antibodies [although Mertens *et al.* (1993) found some co-existence].  $\delta$  subunits were present in only 11% of all the receptors in rat brain but

TABLE 1  
Methods for recognition of  $\gamma$ -aminobutyric acid<sub>A</sub> receptor subtypes in situ

Method	Requirements
1. High-resolution labeling methods a. Immunofluorescence b. Immunocytochemical reaction c. Freeze-fracture/antibody labeling d. Antibody labeling in postembedding electromicroscopy <sup>a</sup>	Spatial separation of receptor subtypes must be adequate
2. Single cell RT-PCR <sup>b</sup> combined with patch-clamp recording	a. Only one subtype is present  b. Large cells are required c. All the receptor mRNAs present must give rise to the assembled receptor <sup>c</sup>
3. Use of an absolutely subtype-specific drug (e.g., furosemide, for $\alpha_6\beta_{2/3}\gamma_2$ ) <sup>d</sup>	a. Specific for one defined composition; cases will be rare b. Patch-clamping must be applicable, or the drug must be labeled, for in situ binding

<sup>a</sup> For example, using sized gold particles (Nusser *et al.*, 1996).

<sup>b</sup> RT-PCR, reverse transcriptase-polymerase chain reaction.

<sup>c</sup> Examples to the contrary are given by Williamson and Pritchett (1994).

<sup>d</sup> This specificity for this drug has been reported by Korpi *et al.* (1995), but application at the microscopic level of this or any other subtype-specific ligand has not been reported yet. Furosemide as a noncompetitive antagonist selects  $\alpha_4\beta_3\gamma_2$  receptors as well as  $\alpha_6\beta_{2/3}\gamma_2$  receptors, but is 14-fold less active at the former (Wafford *et al.*, 1996).

TABLE 2  
Some of the  $\gamma$ -aminobutyric acid<sub>A</sub> receptor subtypes in specified rat neurons<sup>a</sup>

Neurons	Subunits				Possible subtypes
Olfactory bulb					
Mitral cells	$\alpha_1$	$\alpha_3$	$\beta_2$	$\gamma_2$	
Granule cells	$\alpha_2$		$\beta_3$	$\gamma_2$	A2a3
	$\alpha_5$		$\beta_3$	$\gamma_2$	A5a3
Short-axon cells	$\alpha_1$		$\beta_2$	$\gamma_2$	A1a2
Periglomerular cells	$\alpha_2$	$\alpha_5$			$\delta$
Hippocampus					
Pyramidal cells	$\alpha_2$		$\beta_3$	$\gamma_2$	A2a3
	$\alpha_5$		$\beta_3$	$\gamma_2$	A5a3
Dentate gyrus granule cells	$\alpha_2$		$\beta_3$	$\gamma_2$	A2a3
Most interneurons	$\alpha_1$		$\beta_2$	$\gamma_2$	A1a2
Thalamus					
Relay neurons	$\alpha_1$		$\beta_2$	$\gamma_2$	$\delta$
Reticular nucleus neurons	$\alpha_3$			$\gamma_2$	
Hypothalamus					
Supraoptic nucleus	$\alpha_1$	$\alpha_2$	$\beta_{2,3}$	$\gamma_2$	
Ventromedial, arcuate nuclei	$\alpha_2$		$\beta_3$	$\gamma_2$	A2a3
	$\alpha_5$		$\beta_3$	$\gamma_2$	A5a3
Cerebellum					
Purkinje cells	$\alpha_1$		$\beta_{2,3}$	$\gamma_2$	A1a2
Granule cells	$\alpha_1$	$\alpha_6$	$\beta_{2,3}$	$\gamma_2$	$\delta$ A6a2,A16a2,A06
Golgi type II cells	$\alpha_1$	$\alpha_3$		$\gamma_2$	
Motoneurons					
(Cranial nerve nuclei)					
Facial motor nucleus					
Hypoglossal nucleus	$\alpha_1$	$\alpha_2$		$\gamma_2$	
Trigeminal motor nucleus					
Ambiguous nucleus		$\alpha_2$		$\gamma_2$	

<sup>a</sup> Co-expressed subunits were visualized immunohistochemically at the cellular level. The subunits analyzed here are  $\alpha_1$ ,  $\alpha_2$ ,  $\alpha_3$ ,  $\alpha_5$ ,  $\alpha_6$ ,  $\beta_2$ ,  $\beta_3$ ,  $\gamma_2$ , and  $\delta$  (where the anti- $\beta_2$  antibody used does not distinguish between  $\beta_2$  and  $\beta_3$ , " $\beta_{2,3}$ " is noted). In each combination the subunits of that set not detected are not indicated. Where multiple isoforms of  $\alpha$  or  $\beta$  co-occur, they are not necessarily combined in one receptor molecule; for all the subunits, the co-occurrences shown are within a cell not necessarily within a molecule, and sometimes are within a cell type. [The localizations are from Mohler *et al.* (1996b)].

in 27% of those in rat cerebellum, from which both  $\alpha_6\beta_n\delta$  and  $\alpha_6\beta_n\gamma_2$  combinations can be isolated (Quirk *et al.*, 1995) and where Caruncho and Costa (1994) found in situ that the receptors contain either a  $\gamma$  or a  $\delta$  subunit, but not both, by a label-fracture method. The subunit  $\epsilon$  (which has some similarities to  $\delta$ ) also may replace  $\gamma$  in some cells of the hypothalamus and hippocampus (Whitney *et al.*, 1997).

Receptor gene knock-out can provide additional evidence. In favorable cases it can show the co-occurrence of certain pairs of subunits. Thus, the homozygous mice lacking the  $\alpha_6$  gene also lack the  $\delta$  subunit protein in the cerebellar granule cells and the results obtained support other evidence that  $\alpha_6$  and  $\delta$  are paired in receptors there and not  $\alpha_1$  and  $\delta$  without  $\alpha_6$  (Jones *et al.*, 1997). The specific pharmacology of  $\alpha_6\delta$ -containing receptors was confirmed in vivo in this system (Mäkelä *et al.*, 1997).

#### D. Possibilities for Subunit Stoichiometry

On the basis of the extensive evidence reviewed above, that two isoforms of the  $\alpha$  subunit can sometimes occur in one receptor, the receptors are considered as having two  $\alpha$  places in the pentamer. Pollard *et al.* (1995) supported this by quantitation in the  $\alpha_1\alpha_6$ -containing cere-

bellar receptor. Likewise, Khan *et al.* (1994a,b) and Quirk *et al.* (1994a,b) found that two different  $\gamma$  isoforms can co-occur, although Mossier *et al.* (1994) and Im *et al.* (1995) did not find this; if the former statement holds two  $\gamma$  places can also be in the pentamer. However, it is not known whether any conclusion of this type would apply to the entire native population of GABA<sub>A</sub> receptors. Because  $\delta$  has been observed at some sites (see above) to occur with  $\alpha$  and  $\beta$  subunits only, a plausible model is that either  $\gamma$  or  $\delta$  (and perhaps  $\epsilon$ ) subunits can occupy the  $\gamma$  places (in different receptors). We will give an illustration here, only of the basis on which the theoretical maximum number of receptor compositions may be assessed.

Some of the native GABA<sub>A</sub> receptors may have the stoichiometry  $2\alpha.\beta.2\gamma$  (with the  $\gamma$  subunits in some cases being replaceable by  $\delta$  or by  $\epsilon$ ). Several lines of evidence support this. Thus, for the  $\gamma_2$ -containing receptors, there is evidence from immunoprecipitation analyses (as noted above) that the  $\gamma_2\gamma_3$  pairing within one receptor molecule can occur in some cases (Khan *et al.*, 1994b; Quirk *et al.*, 1994a) and also that a subset of receptors in the cerebellum has the composition  $\alpha_1\alpha_6.\beta.\gamma_{2S}\gamma_{2L}$  (Khan *et al.*, 1994b, 1996). Further, Backus *et al.* (1993) have deduced, by incorporating mutant subunits with altered electrophysiological effects in the recombinant  $\alpha_3\beta_2\gamma_2$  receptor [expressed in human embryonic kidney (HEK) 293 cells], that the  $2\alpha.\beta.2\gamma$  composition best fitted the properties found.

On the other hand, Chang *et al.* (1996), using a similar principle (in oocytes and using  $\alpha_1$ , not  $\alpha_3$  subunits), found that there the evidence apparently favors the  $2\alpha.2\beta.\gamma$  composition. The same stoichiometry also was derived for  $\alpha_1\beta_3\gamma_2$  receptors, when expressed in HEK 293 cells, from the staining ratios of those subunits when separated in Western blots (Tretter *et al.*, 1997). Moreover, the co-occurrence of  $\beta_1$  with  $\beta_3$ , and of  $\beta_2$  with  $\beta_3$  (but not  $\beta_1$  with  $\beta_2$ ), isoforms has been indicated in some of the receptors from rat cortex by immunopurification (Li and De Blas, 1997) and likewise in rat cerebellum (Jechlinger *et al.*, 1998). Benke *et al.* (1994) compared the fractions from rat whole brain containing  $\beta_1$ ,  $\beta_2$ , or  $\beta_3$  subunits by immunoprecipitation and also excluded the  $\beta_1\beta_2$  combination; however, in contrast to the findings just noted, they found that the  $\beta_1\beta_3$  or  $\beta_2\beta_3$  pairings also were absent. Overall, it is desirable to allow for possible  $2\alpha.2\beta.\gamma$  forms in the nomenclature. In view of this situation and of the evidence for  $2\alpha.\beta.2\gamma$  combinations, Li and De Blas (1997) suggested that the ratios of the  $\beta$  and  $\gamma$  subunits in the molecule (within the total of 5) may vary with the isoforms selected.

In the expression of recombinant receptors in either cultured cells or oocytes, any ternary combination of the  $\alpha_i\beta_j\gamma_k$  type tested so far can yield a functional receptor in the membrane (e.g., Kirsch *et al.*, 1995). The limit to

the number of ternary subtypes in vivo apparently is not set by barriers to the co-assembly in certain cases but by the program for gene expression of different isoforms in a given cell. However, in a case where this was tested (Angelotti and Macdonald, 1993), when such an  $\alpha+\beta+\gamma$  set is expressed the ternary combination assembles (as far as the subunits are available) and is maintained at the cell membrane to the exclusion of binary combinations. Within the ternary assemblies, there are no obligate combinations or exclusions of  $\alpha\beta$  pairings known from the co-distribution data at the present resolution limits. However, some exclusions are known (see above) at the  $\gamma\delta$  position. Moreover, the  $\delta$  subunit has a more restricted expression in the brain than  $\gamma$  subunits (Wisden and Seeburg, 1992) and has fewer co-occurrences with other subunits; the same is true for  $\epsilon$  (Whiting *et al.*, 1997), whereas  $\pi$  is clearly detectable in certain peripheral tissues only (Heblom and Kirkness, 1997). Hence those subunits cannot be included on the same basis as the others in permutations of the possible compositions.

An enumeration is obtained on the basis that, for a given subunit set which will form one receptor, there will only be one arrangement and stoichiometry in the molecule. This is found to be so with all other heteromeric proteins containing tightly-bound subunits; for example, there is only one cyclic order of the subunits,  $\alpha, \gamma, \alpha, \beta, \delta$ , present in the population of *Torpedo* acetylcholine receptors (Karlin, 1991). Moreover, with those subunits one does not find that the same receptor type, in a variety of skeletal muscles, can contain another stoichiometry. That constancy and the circular order of subunits around the rosette are fixed by the interactions between the interfaces of different subunits. In the case of a GABA receptor (the recombinant  $\alpha_1\beta_1\gamma_{2S}$ ), supporting evidence for a single configuration in the population, from the homogeneity of the channel properties, has been reported (Angelotti and Macdonald, 1993).

Therefore we do not count all possible permutations ( $n = 36$ ) of 2  $\alpha$  isoforms present (out of the 6), but only those for a fixed order ( $n = 21$ ); likewise, for the others. Splice variants could increase these numbers on the same basis, except that two alternatives from one subunit cannot be assumed to be able necessarily to co-occur. From what is known so far of excluded compositions and the restricted co-occurrence of subunits in certain cases, Barnard (1996a) has suggested that a maximum of the order of 800 combinations, of the types observed so far, would then be calculated. The true number is likely to be far smaller than this, but still much larger than for other known receptor subtypes.

The  $\rho$  subunits apparently assemble separately from the others (discussed below). They do not affect the enumeration above, but can add a few separate subtypes in the total noted above.

#### IV. Principles of the Classification

##### A. Application of Selectivities at the Binding Site for Benzodiazepines and Their Functional Analogs

1. *The choice of a classification system.* As noted above, this modulatory site presently offers by far the richest pharmacology for distinguishing subtypes of the GABA<sub>A</sub> receptors. BZs have no intrinsic activity on mammalian GABA<sub>A</sub> receptors, unlike some of the other modulators such as anesthetics (although such a direct effect of some BZs has been found at invertebrate GABA<sub>A</sub> receptors; Zaman *et al.*, 1992). Most BZs act to enhance the action of GABA by increasing the frequency of channel openings and their bursts (Rogers *et al.*, 1994). This can be explained partly by the ability of BZs to increase the affinity of GABA at its binding site. However, in tonic activation of hippocampal neurons by low GABA concentrations they also can increase the channel conductance (Eghbali *et al.*, 1997).

Some other drugs were found to act in the opposite direction at this site, i.e., to decrease the action of GABA at its receptor (Polc *et al.*, 1982; Braestrup *et al.*, 1982), for which the late Willy Haefely introduced the term "inverse agonist," i.e., having negative efficacy at this site (fig. 1). One ligand class, exemplified by flumazenil, Ro14-7437, ZK 93426, or RP 60503, has such low efficacy (at most subtypes) that they effectively act as antagonists at this site (fig. 1). The wide range of BZs and other ligands active at the same site (table 3) that was examined has led to compounds which discriminate among some of the subtypes. When tested in recombinant subunits expressed (in either *Xenopus* oocytes or transfected mammalian cells) in various combinations, a variety of such effects can be found, as will be detailed

TABLE 3  
Modulators acting at the benzodiazepine (or Bz/ $\omega$ ) site<sup>a</sup>

Chemical class	Examples
1,4-Benzodiazepines	Diazepam
1,5-Benzodiazepines	Clobazam
2,3-Benzodiazepines	GYKI-52322
Imidazobenzodiazepinones	Bretazenil; FG 8205; ZG-63 <sup>b</sup>
Imidazobenzodiazepine carboxamides	Imidazenil
Heterocyclic, annelated 1,4-diazepines	Brotizolam; clotiazepam; Ro 19-4603
Triazolopyridazines	CL 218872
Pyrazoloquinolines	CGS 8216; CGS 9895
Quinolines	PK 9084
Imidazoquinolines	NNC 14-0578 <sup>b</sup> ; U-93631
Imidazoquinazolines	NNC 14-8198 <sup>b</sup>
Benzoquinolizones	Ro 19-8022
Pyrazolopyridines	CGS 20625; ICI 190622
Benzothiepinopyridazinones	Y-23684 <sup>b</sup>
Thienopyrimidines	NNC 14-0590
Imidazopyridines	Zolpidem
Imidazopyrimidines	Divaplon; Ru 33-203
Cyclopyrrolones	Zopiclone, suriclone
$\beta$ -Carbolines	Abecarnil

<sup>a</sup> The examples chosen are positive modulators on at least some of the GABA<sub>A</sub> receptor subtypes; some may also be negative modulators at other subtypes.

<sup>b</sup> ZG-63 (Wong *et al.*, 1993); NNC 14-0578/NNC 14-8198 (Wong *et al.*, 1995); Y-23684 (Yasumatsu *et al.*, 1994).

TABLE 4  
 Classification of some of the  $\gamma$ -aminobutyric acid<sub>A</sub> receptors

GABA <sub>A</sub> receptor subtype	Composition <sup>a</sup>	Characteristic properties
A1a	$\alpha_1 \beta_n \gamma_2$	High affinities and efficacies for classical BZ agonists, <sup>b</sup> CL 218872 (partial agonist), zolpidem, 2'-oxoquazepam <sup>c</sup>
A1b	$\alpha_1 \beta_n \gamma_3$	Same as for A1a, but ~400-fold less sensitive to zolpidem and affinities are lower for 2'-oxoquazepam (in the same range as for A2, A3, and A5) and for classical BZ agonists <sup>d</sup>
A1c	$\alpha_1 \beta_n \gamma_1$	Same as for A1b, but flumazenil and Ro 15-4513 have low affinity and act, like $\beta$ -carbolines (inverse agonists at A1a,b), as low-potency positive agonists <sup>e</sup>
A2a	$\alpha_2 \beta_n \gamma_2$	Similar to A3 for the ligands noted there, but other properties not yet defined
A2c	$\alpha_2 \beta_n \gamma_1$	BZ/ $\omega$ agonists have 2- to 20-fold lower potency than on A2a, with FG8205 the most selective. The affinity of zolpidem is 5-fold greater on A2c but with very low efficacy. Insensitive to antagonists (e.g., flumazenil, CGS-8216, and Ro 15-4513). DMCM is an agonist <sup>f</sup>
A3a	$\alpha_3 \beta_n \gamma_2$	High affinities and potencies for classical BZ agonists and $\beta$ -carbolines, similar to those of A1, but intermediate for zolpidem, for CL 218872 and 2'-oxoquazepam, ~10-fold lower than on A1a <sup>g</sup>
A4a	$\alpha_4 \beta_n \gamma_2$	Insensitive to classical BZ agonists, zolpidem and many other BZ/ $\omega$ agonists. Notable exceptions are bretazenil, CGS 20625, and some pyrazoloquinolines. Intermediate affinities for most $\beta$ -carbolines inverse agonists (~10 times higher than at $\alpha_6 \beta_n \gamma_2$ ), but high affinity for DMCM. Flumazenil and Ro 15-4513 are agonists. The direct activation by propofol or pentobarbital is absent <sup>h</sup>
A5a1	$\alpha_5 \beta_{1/3} \gamma_2$	A5: High affinity for classical benzodiazepine agonists but insensitive to imidazopyridines. Intermediate affinity for CL218872 and 2'-oxoquazepam. Certain 8-acetylenic imidazobenzodiazepines (inverse agonists) and L-655,708 (BZ/ $\omega$ agonist) are highly selective
A5b3	$\alpha_5 \beta_3 \gamma_3$	Affinities of A5b3 are as for A5a1, but triazolam and $\beta$ -carbolines are ~10- to 30-fold weaker and CL 218872 is 10-fold stronger
A5a2	$\alpha_5 \beta_2 \gamma_2$	A5a1 differs from A5a2 in its outward rectification and its slower desensitization at depolarized voltages <sup>i</sup>
A6a1	$\alpha_6 \beta_1 \gamma_2$	Insensitive to all BZ/ $\omega$ ligands except bretazenil and some other partial agonists; flumazenil and Ro 15-4513 become partial agonists and DMCM an antagonist (fig. 5)
A6a2	$\alpha_6 \beta_{2/3} \gamma_2$	Same as for A6a1, but A6a2 is antagonized selectively by furosemide (see notes to table 1)
A16a2	$\alpha_6 \alpha_1 \beta_{2/3} \gamma_2$	Combines the binding sites of A1a and A6a2 <sup>j</sup>
A0r		A0r: insensitive to all BZ/ $\omega$ ligands, but also to bicuculline and pentobarbital. Not activated by isoguvacine
A0r1	$\rho_1$	
A0r2	$\rho_2$	
A0r12	$\rho_1 \rho_2$	A0r12 (alone) has very low sensitivity to picrotoxin (in the rat) (for references: see Sections I.A. and IV.D.)
A0r3	$\rho_3$	
A01, A02		Insensitive to all BZ/ $\omega$ ligands, not because of $\rho$ , but (e.g.) $\alpha + \beta + \delta$ or $\alpha + \beta + \epsilon$ . Sensitive to bicuculline
A01	$\alpha_1 \beta_n \delta$	Same as above, and highly sensitive to zinc
A04	$\alpha_4 \beta_n \delta$	Generally similar to A01
A06	$\alpha_6 \beta_n \delta$	Same as for A01; in cerebellar granule cells only <sup>k</sup>
A01e	$\alpha_1 \beta_n \epsilon$	Generally similar to A01

<sup>a</sup> This means that, e.g., the GABA<sub>A2a</sub> receptor has a pharmacology which mimics that of the co-expressed recombinants  $\alpha_2 \beta_n \gamma_2$ , where  $n = 1-3$  (in tests so far), unless distinctions are known because of the  $\beta$  isoform present;  $\beta_{1/3}$  means  $\beta_1$  or  $\beta_3$ . The stoichiometry within the assembly is not implied. Both binding affinities and effects on GABA-evoked currents are considered in the pharmacologies compared in column 3. For ease of comparison here, in the second column the isoform numbers are not written as subscripts (which will be the correct general usage). Species differences in these receptors can occur within the mammals; where possible, data on the human receptors have been used here but, where not available, data on the rat are used. In general, the rule of preference, failing available human receptor pharmacology, will be rat, then other mammals, then birds.

<sup>b</sup> Classical BZ agonists are diazepam, flunitrazepam, clonazepam and other BZs of similar activity. Except where noted otherwise, flumazenil is an antagonist and Ro 15-4513 is a partial inverse agonist, both with high affinity.

<sup>c</sup> Likewise for most inverse agonists at the BZ site, for example  $\beta$ -carboline, ethylcarboxylate, and Ro 19-4603.

<sup>d</sup> Herb *et al.* (1992); Luddens *et al.* (1994); Hadingham *et al.* (1995).

<sup>e</sup> Ymer *et al.* (1990); Puia (1991); Giusti *et al.* (1993).

<sup>f</sup> Wisden and Seeburg (1992); Hadingham *et al.* (1993); Wafford *et al.* (1993). Apart from possible locations on some brain neurons, A2c is the subtype on cerebellar Bergmann glia and on  $\alpha$  cells of the pancreas.

<sup>g</sup> For example, "high affinity" for zolpidem would cover reported  $K_i$  values (for the rat receptors), for  $\alpha_1 \beta_{(1-3)} \gamma_2$  of 19 to 30 nM and "intermediate affinity" would cover 688 nM  $K_i$ , or 650 nM  $EC_{50}$  in potentiation of the GABA-evoked current (Faure-Halley *et al.*, 1993; Luddens *et al.*, 1994).

<sup>h</sup> Yang *et al.* (1995); Huh *et al.* (1996); Knoflach *et al.* (1996); Scholze *et al.* (1996); Wafford *et al.* (1996).

<sup>i</sup> A5: Pritchett and Seeburg (1990); Faure-Halley *et al.* (1993); Hadingham *et al.* (1993). A5a1 (which, in the  $\gamma_{2L}$  form, resembles a native receptor in CA1 pyramidal neurons): Burgard *et al.* (1996). A5b3: Luddens *et al.* (1994); Hadingham *et al.* (1995). A5a2: Burgard *et al.* (1996). 8-Acetylenic imidazobenzodiazepines and L-665,708 (tested so far on  $\alpha_n \beta_2 \gamma_2$  receptors): Liu *et al.* (1996); Quirk *et al.* (1996).

<sup>j</sup> A6: On A6a1/A6a2, partial agonists bretazenil and CGS-9895 and the antagonist flumazenil show 44 to 270 nM  $K_i$  values (human, rat). A16a2 has high-affinity flumazenil and Ro 15-4513 binding sites, diazepam-sensitive. References: A6a1, A6a2, Luddens *et al.* (1990); Korpi *et al.* (1995); Yang *et al.* (1995); Hadingham *et al.* (1996); Huh *et al.* (1996); Nusser *et al.* (1996); Wafford *et al.* (1996). A16a2: Pollard *et al.* (1995); Khan *et al.* (1996).

<sup>k</sup> A01: Saxena and Macdonald (1994); Ducic *et al.* (1995). A06: Quirk *et al.* (1995); Saxena and Macdonald (1996); Jones *et al.* (1997).

below. For those cases where subtypes are established, the nomenclature for them ideally would be based only on molecular biology and would express the subunit composition, e.g., the " $\alpha_1\beta_2\gamma_2$ " subtype (which then could be abbreviated as GABA<sub>A122</sub>, etc.). Even this scheme would be cumbersome to use, e.g., needing expansion to cover all the subunit forms, etc., as discussed in Section IV.B. below. It is acceptable for stating the composition of an experimentally expressed mixture of recombinant subunits (but this entails some simplifications, detailed in Section IV.B.). In contrast, it generally cannot be known in practice what this subunit composition is for the native receptors whose function is being measured by any current methodologies. In summary, a receptor composition (but not its stoichiometry) can be proposed in some cases of artificial co-expression in a heterologous system, but this does not classify native receptors.

Approaches are now being made to identifying some of the compositions of native GABA receptors in situ: the methods presently available for this are listed in table 1. It can be seen that these are very limited so far, and usually will not specify the stoichiometries of the subunits identified. In none of the cases where these methods have been used has an unambiguous correspondence to pharmacological activity in vivo been feasible. One potential exception would be method 2 of table 1, which was applied to single cells in the thin-slice recording system (Santi *et al.*, 1994). In situ identifications of co-occurring subunits that have been obtained with method 1a are exemplified in table 2.

Thus, the methods listed in table 1 cannot deal as yet with the wide range of the subtypes nor overcome the resolution problems for most native situations of co-occurring multiple subtypes. Therefore, for an assignable and practical nomenclature, we are driven to using a pharmacologically based system. However, the hard information being obtained by recombinant receptor expression studies, e.g., that the  $\gamma_1$  subunit always introduces atypical modulatory effects of BZs, acts as a constraint and must be kept in view when assigning the pharmacologies. This is done in table 4, using the only site on the GABA<sub>A</sub> receptors at which a sufficient pharmacology yet exists, the site binding BZs. When an in situ composition becomes firmly established for a given subtype, recombinant co-expression of that set of subunits to display the pharmacology of that subtype should establish or confirm its assignment in table 4.

Examples cited in this text show that there may not always be agreement on the evidence for co-assembly in vivo of a particular set of subunits. Independent confirmation thus is needed before a definite assignment is accepted.

**2. Benzodiazepine-responsive  $\gamma$ -aminobutyric acid receptor subtypes.** To obtain receptors expressing properties most closely resembling those of BZ-responsive GABA<sub>A</sub> receptors on neurons, recombinant  $\alpha$ ,  $\beta$ , and  $\gamma$  subunits are required to be co-expressed (as reviewed by

Macdonald and Olsen, 1994 and McKernan and Whiting, 1996). Some  $\alpha\gamma$  or  $\beta\gamma$  combinations can reproduce many of those native properties but never in the full range that has been observed in vivo; the variety of functional patterns which has been observed with different  $\alpha\gamma$  or  $\beta\gamma$  combinations in vitro is detailed, with references, in Section III.B. of Sieghart (1995). It neither has been demonstrated nor excluded that some binary combinations exist in vivo, but if they do, this must be to a small extent in numbers or in locations. If such exist, the assumption is made that they are pentameric. If the  $\alpha_4$  and  $\alpha_6$  isoforms are used in  $\alpha\beta\gamma$  combinations, however, a different type of activity is produced; the effect varies with the modulator (table 4, fig. 5), but classical BZ full agonists such as diazepam and midazolam have greatly reduced affinities (Wisden *et al.*, 1991; Kleingoor *et al.*, 1991; Yang *et al.*, 1995; Scholze *et al.*, 1996).  $\beta$ -Carboline inverse agonists can be active on these subunit combinations but usually with much lower affinity, especially for the  $\alpha_6\beta_2\gamma_2$  combination (Kleingoor *et al.*, 1991; Yang *et al.*, 1995; Knoflach *et al.*, 1996). From a wide range of recombinant studies of that kind, several




FIG. 5. Modulation of EC<sub>20</sub> responses to GABA by BZ and  $\beta$ -carboline ligands. **a**, Modulation of GABA EC<sub>20</sub> responses by BZ ligands in oocytes injected with  $\alpha_1\beta_1\gamma_2s$ ,  $\alpha_6\beta_1\gamma_2s$ , and  $\alpha_4\beta_1\gamma_2s$ . **b**, Modulation of GABA EC<sub>20</sub> responses by  $\beta$ -carboline ligands in oocytes injected with  $\alpha_1\beta_1\gamma_2s$ ,  $\alpha_6\beta_1\gamma_2s$ , and  $\alpha_4\beta_1\gamma_2s$ . All compounds were examined at a concentration of 1  $\mu$ M, and the data shown are the mean  $\pm$  standard error for at least four oocytes. From Wafford *et al.* (1996). The three groups represent the A1a1, A6a1, and A4a1 subtypes of table 4.

such ternary combinations have been distinguished, in fact; the  $\alpha$  subunit isoform present exerts a major effect on the affinity and efficacy of ligands at the BZ site, as shown in table 4.

The BZs themselves are rather poor tools to make these distinctions; compounds of quite different structures but with BZ-like activities are more effective. These include (fig. 2; table 3) triazolopyridazines, pyrazoloquinolines, heterocyclic annelated 1,4-diazepines, imidazopyridines, cyclopyrrolones,  $\beta$ -carboline, etc. Table 4 shows that a variety of pharmacologies can be found using these modulators as probes, both those with positive and some with negative efficacy. These properties are produced experimentally by the recombinant subunit combinations shown; the main value of this approach for classification lies in the possibility of recognizing those individual pharmacologies in native receptors. We therefore *recommend* that the subtypes of the GABA<sub>A</sub> receptor should be designated as a series, GABA<sub>A1</sub>, GABA<sub>A2</sub>, etc.

The isoform of the  $\gamma$  subunit which is also present can modify the effect of the  $\alpha$  isoform. The  $\gamma_2$  subunit mRNA is much more abundant in the brain than that for  $\gamma_3$  or  $\gamma_1$ , and the great predominance of the  $\gamma_2$  subunit is confirmed by the results seen with  $\gamma_2$ -less transgenic mice, in which the BZ-binding sites and the BZ sensitivity of the GABA<sub>A</sub> receptors are virtually totally extinct (Günther *et al.*, 1995). Positive modulation by most BZ-type agonists is reduced when  $\gamma_2$  is replaced by  $\gamma_1$ , and inverse agonists ( $\beta$ -carboline) then become agonists (Puia *et al.*, 1991; Giusti *et al.*, 1993). Flumazenil is bound much more weakly when  $\gamma_1$  is present (Ymer *et al.*, 1990) and changes from an antagonist to a BZ agonist (Wafford *et al.*, 1993). Hence the  $\gamma_1$ -containing receptors can be classified separately. A specific but lesser effect is known for the replacement of  $\gamma_2$  by  $\gamma_3$ , as in the  $\alpha_1$ - and  $\alpha_5$ -containing receptors (table 4). If  $\gamma$  is replaced by  $\delta$  (or  $\epsilon$ ) none of these pharmacologies apply and new (BZ-insensitive) subtypes are created (Wisden and Seeburg, 1992; Saxena and Macdonald, 1994, 1996). Native subtypes exist in the rat cerebellum which contain  $\delta$  and have no high-affinity BZ binding (Quirk *et al.*, 1995).

It will be only an initial simplification to classify the receptors on the basis of their  $\alpha$  or  $\gamma$  or  $\delta$  or  $\epsilon$  subunit content, because of the other subunits present in the molecule. In future extensions, further subsubtypes would be listed based on a constant  $\alpha$  subunit and variable  $\beta$  and  $\gamma$ , where these are shown to define specific subpharmacologies.

The subdivisions are made on the principle of the economy of classification, in that subcategories are not set up for every theoretical combination with  $\gamma$  or  $\beta$  isoforms (combinations which often may not exist in the nervous system), but only for those where functional discrimination is needed.

**3. Notation.** For identifying the subunits, the Greek letters already in use are acceptable for IUPHAR usage,

for that purpose; their isoform numbers must be subscripts to them, as written in this text.

For the receptor subtypes notation, however, it should be remembered that we are constrained to keep to the IUPHAR general numbering scheme, intended to be uniform for all receptors and for ease of entering subtypes in information systems (Vanhoutte *et al.*, 1996). Hence, Greek letters, further subscripts, internal separations by dots, and other typographical devices not used here are not permitted for the subtypes.

Conforming with these requirements, in the system used GABA is given as the receptor type and all the rest follows as a subscript to it. **A** is the designator of every GABA<sub>A</sub> receptor. In the first position after this, for all of the "BZ-sensitive GABA<sub>A</sub> receptors," i.e., those responding in some manner to BZ/ $\omega$  ligands, there is a numeral showing the  $\alpha$  subunit isoform which would be needed for the behavior seen. In the successive positions (more accurately, fields) after this, an alternation is use of letters (lower case) and numerals for further pharmacological subsets. This allows more than one letter (or numeral) to be used in the same field where desired (particularly for any co-occurrence of two isoforms of one subunit) without causing confusion with the adjacent fields. Because a  $\gamma$  subunit is needed in all the known cases having a BZ site, in the second field there is a lower-case letter designating the  $\gamma$  subunit isoform also involved; these are named in order of abundance in the brain. Because  $\gamma_1$  will rarely be involved, **a** denotes  $\gamma_2$ , **b**  $\gamma_3$ , and **c**  $\gamma_1$ .

In the third field after **A**, there is another numerical series, used only when the choice of  $\beta$  isoform has been shown to be significant. The number of the  $\beta$  isoform then is added here. Where, as often occurs, the  $\beta$  isoform present cannot be deduced from the pharmacology studied, this can be omitted, or *n* can be used. Where either of 2 alternative isoforms is known to give the described pharmacology (e.g.,  $\beta_{1/3}$ ), the lowest number is cited. If receptors are identified which are differentiated pharmacologically because of the presence of two isoforms of the  $\beta$  subunit, then both numerals are used, e.g., 13 denotes the co-occurrence of  $\beta_1$  and  $\beta_3$  subunits. Likewise, if pharmacologically differentiated receptors containing multiple isoforms of  $\gamma$  are identified, they can be designated by their two letters in the second field, e.g., **ab** for  $\gamma_2\gamma_3$ . According to present evidence (Khan *et al.*, 1994b; Quirk *et al.*, 1994a) that is the only pairing which occurs of the  $\gamma$  isoforms (apart possibly from pairs of  $\gamma_2$  splice variants, encoded below). Present evidence generally indicates that a  $\gamma$  subunit does not co-occur with a  $\delta$  or  $\epsilon$  subunit in the BZ-sensitive receptors, but if such a case were to be established as a native receptor, then identifying English letters could be assigned to  $\delta$  or  $\epsilon$  when added in that field.

For splice variants, where a functional difference is known, (l) or (s) (for longer and shorter forms) can be added after the designating letter, because a single



length change specifies each case so far. This must be in lower case and in parentheses for the uniform system (Vanhoutte *et al.*, 1996). This would need extension when more complex splicing is discovered.

The GABA<sub>A</sub> receptors insensitive to BZ/ $\omega$  ligands are described as A0. Where this is because of  $\delta$  or  $\epsilon$ , for example, they then are numbered on the same principles as above. Where it is because of the  $\rho$  subunit, these are the A0r receptors, numbered as shown in table 4. If it is confirmed that a receptor can mix  $\rho$  and other subunit types, then additions based on the aforementioned principles can be made to the A0r numbers.

An example from the recent literature which can illustrate the functional classification is given in fig. 5 (Wafford *et al.*, 1996). This shows the differences in the responses to various modulators at this site which define pharmacologies in the A1, A4, and A6 groups of table 4. Note how a given ligand can be an agonist, an inverse agonist, or an antagonist as the  $\alpha$  subunit is varied.

### B. Advantages and Possible Modification of the Classification

The advantages of the classification of table 4 are:

- (i) At a glance this classification shows for which putative subunit compositions a pharmacological recognition of a subtype is possible with the present tools. The primary criterion for the classification is the defined functional behavior.
- (ii) The many potential compositions for which no pharmacological distinction is known do not confuse the classification.
- (iii) It indicates similarities or differences between structurally related receptors.
- (iv) For a case to be listed in table 4, some evidence should exist, obtained (for example) by the methods of table 1 or by immunoprecipitations, that the receptor subtype noted occurs *in vivo*. For example, a general finding from such studies is that  $\alpha_1\beta_2\gamma_{2L/S}$  and  $\alpha_1\beta_1\gamma_{2L/S}$  are common compositions existing *in situ*, and hence A1a1 and A1a2 are confirmed subtypes.

Despite these considerations, some may prefer to refer to a given subtype by its putative composition from column 2 of table 4. This alternative notation can be used, but it should be made clear that this is not a statement that the receptor has this absolute composition, but denotes a recombinant set of subunits which mimics the properties of a native receptor, so far as has been tested. Because not all receptor properties necessarily can be compared and because a multiplicity of native receptors occurs at most locations, this correspondence does not establish that a single native GABA<sub>A</sub> receptor has that precise composition. In one or two favorable cases this can become very probable. In some others a distinctive pharmacology may be definable with a set of recombinant subunits assembling in a foreign

cell type, but with no certainty that it occurs *in situ*. As one example, the  $\delta$  subunit readily assembles functionally with  $\alpha_1$  or  $\alpha_6$  (plus  $\beta$ ) subunits in transfected mammalian cells (Saxena and Macdonald, 1994, 1996; Krishek *et al.*, 1996), but in the granule cells in the cerebellum, which contains all these subunits (and  $\gamma_2$ ),  $\alpha_6\beta\delta$  and  $\alpha_1\beta\gamma_2$  are expressed strongly, but  $\alpha_1\beta\delta$  is undetectable, as shown both by co-immunoprecipitation (Quirk *et al.*, 1994b) and by gene knock-out manipulations (Jones *et al.*, 1997). If this alternative usage is applied to a native receptor, the term "like" must be added, as in " $\alpha_2\beta_n\gamma_1$ -like GABA<sub>A</sub> receptor" instead of "GABA<sub>A2c</sub> receptor." The former terminology is itself a simplification and cannot readily be used universally. Thus, additional notations would be needed to denote the subunit types that occur in pairs (when these become known), and further to denote those which occur in nonidentical pairs or as splice variants, and to allow for the combinations containing subunits other than the  $\alpha$ ,  $\beta$ , and  $\gamma$  types. Also, the functional species present after co-expression may vary with the proportions of the different cDNAs (or RNAs) used, which would have to be specified (using the coding region lengths) unless independence thereof has been documented. In some cases, mixtures of active products may be generated; it is particularly difficult to use this approach for a receptor containing two isoforms of one subunit type, e.g.,  $\alpha_1\alpha_3\beta_n\gamma_2$ . Further, several cases have been found in which the host cell used for the co-expression influences the properties observed; the disparities are usually between expression in the oocyte and in a mammalian cell line, but even different cell lines may affect the outcome, perhaps because posttranslational changes. Examples of these disparities are given in Section III.B.7. of Sieghart (1995).

All these limitations should be considered before it is asserted explicitly or by implication in the terminology that a given co-expression in a nonneural cell of subunit cDNAs (or RNAs) is equivalent to a specific native GABA<sub>A</sub> receptor.

### C. Nomenclature for the Site Binding Benzodiazepines and Modulators with Similar Activity

Discussion of this modulatory site and its ligands is necessarily so frequent in the classification of GABA<sub>A</sub> receptors that a succinct name is clearly a necessity. It would be ideal to name this site for a natural modulatory ligand. However, whereas several endogenous potential ligands have been identified, the physiological relevance of these compounds is presently unclear. Synthetic ligands active at this site can be defined operationally as those whose binding is inhibited competitively at this site by a known BZ antagonist or partial inverse agonist such as flumazenil, CGS 8216, Ro15-4513, or RP60503.

Initially this site was recognized by the action of many 1,4-BZs (figs. 1, 2) and hitherto it has been referred to as "the BZ site," but this nomenclature now requires fur-

ther consideration. It raises the following issues, among others:

(a) Discrimination of subtypes through this site, in practice, usually is made by ligands that are not BZs, but represent a diverse range of chemical structures, as named in table 3.

(b) BZ binding sites occur in other, entirely different, receptors, which also are commonly named for that drug class, i.e., the BZp discussed above. The "BZ site" on those receptors has no relation to the site on GABA<sub>A</sub> receptors.

(c) There are other types of BZ binding sites, apart from BZp, of pharmacological significance, not on GABA receptors. These include, among others, the sites for 2,3-BZs, such as GYKI-52322, which are abundant in certain brain regions, in a pattern very distinct from that of 1,4-BZ binding (Horvath *et al.*, 1994). Some of these sites are on non-N-methyl-D-aspartate glutamate receptor channels and there is no activity on GABA<sub>A</sub> receptors (Bleakman *et al.*, 1996). Hence, when "BZ sites" in the CNS are discussed, one ought to distinguish between sites for 1,4-BZs, for 1,5-BZs (which affect likewise some GABA<sub>A</sub> receptor subtypes), and those for 2,3-BZs, all of which include drugs in current pharmacological use. At least some qualification is needed to exclude the ligands for receptors other than GABA<sub>A</sub> receptors.

It has been argued, however, that the term "BZ site" is used so widely, even when other structures are being used for studying or exploiting it, that it would be confusing to replace it by an unfamiliar term. There is no chemical class which will encompass all of the diverse ligand types for this site which are now in use, so no self-explanatory term can be substituted. A neutral term not hitherto used for receptor subtypes, "omega ( $\omega$ ) site," has been proposed for it (Langer and Arbilla, 1988) but this has the drawback of not being at once recognizable in this context. It could be made so by retaining "BZ" with it, as "BZ/ $\omega$ ."

Therefore, the following *recommendation* is made: Sites of GABA<sub>A</sub> receptors at which modulation of GABA activation occurs by BZs and other ligands of related activity (even if different in chemical structure) should continue to be termed "the BZ site (or sites)" or, as an acceptable option, the "BZ/ $\omega$  site." It is not recommended to add numbers to the BZ or BZ/ $\omega$  terminology, but if this is done, then the numbering should follow the GABA<sub>A1</sub> to GABA<sub>A6</sub> (etc.) numbering system. The terms "BZ receptor" or "GABA/BZ receptor" or "omega receptor" should no longer be used.

In this review the term "BZ site" will be used, but also "BZ/ $\omega$  ligands" for clarity where non-BZ modulators at this site are being included. The latter option seems to be a clearer term for these ligands in that instance.

#### D. Benzodiazepine Insensitivity

A minority of GABA<sub>A</sub> receptors detected in the nervous system are not modulated at all at the BZ site

(Unnerstall *et al.*, 1981; Polenzani *et al.*, 1991; Rovira and Ben-Ari, 1991; Sivillotti and Nistri, 1991; Quian and Dowling, 1993; Quirk *et al.*, 1995). The nomenclature proposed here includes an additional GABA A0 class for these receptors. Because insensitivity to BZ/ $\omega$  ligands can arise by different molecular mechanisms, we would need GABA<sub>A01</sub>, GABA<sub>A02</sub>, etc. However, because one form of insensitivity at this site arises from the presence of a  $\delta$  subunit or of an  $\epsilon$  subunit in some situations, whereas another could potentially arise from the presence of  $\alpha$  and  $\beta$  subunits alone, it seems more self-consistent to include these as shown in table 4. More information is needed on the presence of these various pharmacologies in native receptors before we can decide on detailed A0 series assignments.

The  $\pi$  subunit also produces BZ-insensitive receptors with  $\alpha$  and  $\beta$  subunits in vitro (Heblom and Kirkness, 1997) and could therefore yield another subset of the A0 class. However, study of the  $\pi$  subunit has only just begun and as yet there are no clues as to its partners in vivo. Because its expression apparently does not occur in the brain but is in a few peripheral nonneuronal locations, potential combinations of  $\pi$  there with subunits exclusive to the brain can be ignored pending further information and it is not included in table 4.

One class of receptors insensitive to BZ/ $\omega$  ligands clearly needs to be numbered separately, because its structural basis is so different. These are the ionotropic GABA receptors which are also insensitive to bicuculline and to barbiturates (Bormann and Feigenspan, 1995; Johnston, 1996), described previously as "GABA<sub>C</sub> receptors," as discussed earlier in this review. This receptor type contains the  $\rho_1$ ,  $\rho_2$ , or  $\rho_3$  subunits (Section III.A.), all three of these subunits being highly expressed in the retina (Cutting *et al.*, 1991; Enz *et al.*, 1995; Ogurusu *et al.*, 1997).

These receptors are distinguished also by their insensitivity to the GABA agonist isoguvacine (Woodward *et al.*, 1993) and by their activation by *cis*-4-aminopent-2-enoic acid [*cis*-4-aminocrotonic acid (CACA)] (Kusama *et al.*, 1993a). CACA is essentially inactive at a wide range of the other GABA<sub>A</sub> receptors (Johnston, 1996); however, CACA may not be fully diagnostic for the  $\rho$ -containing receptors because it is active on certain bicuculline-sensitive GABA receptors in hippocampal cells (Strata and Cherubini, 1994). Because, as noted above, the  $\rho$  subunits do not (so far as is known) co-assemble with other GABA<sub>A</sub> receptor subunits, we designate the  $\rho$ -containing receptors as a separate series, A0r. In the rat retina the bicuculline-resistant form of the receptor is also picrotoxin-resistant and is mimicked by expressed recombinant  $\rho_1\rho_2$  heteromeric receptors (Zhang *et al.*, 1995) and not by rat or human  $\rho_1$  or  $\rho_2$  homomers (Kusama *et al.*, 1993b; Wang *et al.*, 1994; Zhang *et al.*, 1995) nor by  $\rho_3$  homomers (Shingai *et al.*, 1996). Hence one can define, on present knowledge, A0r1, A0r2, A0r3, and A0r12 as subtypes in this series.

Pharmacologies corresponding to some of these recombinant oligomers have been observed in retinal rod bipolar cells (Bormann and Feigenspan, 1995). Further  $\rho$ -containing subtypes, if established as native receptors, would be numbered on the same principle. Whether A0r1, A0r2, and A0r3 occur in situ as homomeric functional receptors (and whether the  $\rho_1\rho_3$  combination occurs) is not yet known.

## V. Chromosomal Localization of $\gamma$ -Aminobutyric Acid<sub>A</sub> Receptor Genes

This topic is relevant to the subunit composition of the receptor subtypes, because it has been found that the genes for the considerable number of subunits involved occur in clusters, three or four at each locus, on human chromosomes. The first of these genes to be localized (Buckle *et al.*, 1989) were those for the  $\alpha_1$ ,  $\alpha_2$ ,  $\alpha_3$ , and  $\beta_1$  subunits, which are spread among three chromosomes. However, subsequent localizations of other subunit genes show that the genes actually occur in groups (fig. 6). (References are:  $\alpha_4$ , McLean *et al.*, 1995;  $\alpha_5$ , Knoll *et al.*, 1993;  $\alpha_6$ , Hicks *et al.*, 1994;  $\beta_2$ , Russek and Farb, 1994;  $\beta_3$ , Wagstaff *et al.*, 1991 and Glatt *et al.*, 1997;  $\beta_4$ ,  $\epsilon_1$ , Levin *et al.*, 1996 and Whiting *et al.*, 1997;  $\gamma_1$  and  $\gamma_2$ , Wilcox *et al.*, 1992;  $\gamma_3$ , Gregor *et al.*, 1995).

Each cluster contains genes of the  $\alpha$ ,  $\beta$ , and  $\gamma/\epsilon$  classes, in line with the composition of most of the receptor subtypes. Selective gene clustering on this scale is unprecedented for a receptor. Where the gene order has been determined so far, it is  $\gamma/\epsilon$ - $\alpha$ - $\beta$ . These phenomena suggest a possible relationship to subunit co-expression. McLean *et al.* (1995) have proposed that these clusters are derived by a series of gene duplication events from a single ancestral  $\alpha\beta\gamma$  gene cluster. Also, two isoforms of  $\alpha$  genes can co-localize (fig. 6), in line with the co-occurrence of two  $\alpha$  isoforms in one receptor that has been noted frequently (as described above).

The  $\delta$  subunit has become separated from these clusters, on chromosome 1 (Sommer *et al.*, 1990). The two  $\rho$  subunit genes that have been mapped,  $\rho_1$  and  $\rho_2$  (subunits which co-assemble), lie together on human chromosome 6 or mouse chromosome 4 (Cutting *et al.*, 1992).

## VI. Other Binding Sites in Relation to the Receptor Classification

### A. Other Modulatory Sites

It must be emphasized that all the classifications of table 4 are provisional. As more BZ/ $\omega$  ligands that can




FIG. 6. Chromosomal clusters (shown in boxes) of genes for GABA<sub>A</sub> receptor subunits.

discriminate receptor subtypes are found, as differential effects of non- $\alpha$  subunits are explored further, and as the other modulatory sites are compared on many subtypes, extensions and revisions certainly will be needed. Thus, assistance in subclassifying the A1 to A6 series should come from criteria based on ligands recognizing particular  $\beta$  or  $\gamma$  isoforms. Loreclezole is a GABA-potentiating drug which does not act at the BZ site but which recognizes the presence of both  $\beta_2$  and  $\beta_3$  but not  $\beta_1$  subunits (Wafford *et al.*, 1994). Several anesthetic drugs and neurosteroids (Macdonald and Olsen, 1994; Sieghart, 1995) also act as potentiators of GABA (and in some cases as direct activators), but high subunit selectivity has not been found as yet. The anesthetic etomidate has a very strong preference for direct activation, for a  $\beta_2$  or  $\beta_3$  over a  $\beta_1$  subunit, which a residue in the  $\beta$  TM2 domain affects (Belelli *et al.*, 1997). The propofol and pentobarbital sites for *direct* activation of the receptor are diagnostic (in the  $\gamma_2$ -containing series) for receptors containing  $\alpha_4$ ; only the presence of  $\alpha_4$  abolishes that effect (Wafford *et al.*, 1996). Recombinant  $\alpha_1\beta_n\epsilon$  or  $\alpha_2\beta_n\epsilon$  receptors lack the GABA potentiation response to these drugs (Davies *et al.*, 1997) and the BZ modulation. Because there is no information on the  $\epsilon$  combinations existing in situ, they are omitted from table 4.

Modulatory binding sites which differ from any of those recognized previously in the GABA<sub>A</sub> receptors have been discovered more recently. These include a site for certain pyrazinones that potentiate GABA action (Im *et al.*, 1993a) and a site for some dihydroimidazoquinolines (Im *et al.*, 1993b). The subunit specificity in these series has yet to be established. Furosemide is a more specific example; it is an antagonist (at a separate site) with a high selectivity at  $\alpha_6\beta_{2/3}\gamma_2$  (Korpi *et al.*, 1995) and a somewhat lower selectivity at  $\alpha_4\beta_{2/3}\gamma_2$  receptors (Wafford *et al.*, 1996). Thus, in oocyte expression the IC<sub>50</sub> values were 6  $\mu$ M and 160  $\mu$ M, respectively, but >5 mM with all other combinations tested. Drugs of this character could provide a tool for recognizing such subunit combinations as subtypes in the CNS. Other such cases can be expected to be found as medicinal chemistry is applied systematically, using expressed subunit combinations as screening systems.

### B. The $\gamma$ -Aminobutyric Acid Recognition Site

Selectivity among subtypes for the GABA agonists available to date has not been high. Ebert *et al.* (1994) and Wafford *et al.* (1996) have described the concentration-response curves for four GABA agonists in recombinant  $\alpha\beta\gamma$  receptors, varying the  $\alpha$ ,  $\beta$ , and  $\gamma$  subunit isoforms. Effects of the  $\alpha$  and  $\gamma$  isoform and (less) of the  $\beta$  isoform were found, but these were not primarily of diagnostic value. The largest difference was that with  $\alpha_4$  (but not  $\alpha_6$ ) present, where the intrinsic activity with piperidine-4-sulfonic acid was (with  $\beta\gamma_2$ ) exceptionally low (6% at the maximum).

Large differences between the A0r receptors and the others are seen with GABA agonists and with GABA antagonists. The A0r receptor subtypes known so far are all highly resistant to bicuculline, an antagonist for all other subtypes. Some of the typical GABA<sub>A</sub> agonists such as isoguvacine and piperidine-4-sulfonic acid are antagonists or inactive at the A0r receptors. Conversely, CACA is an agonist at A0r receptors but is usually inactive at other GABA receptors (Johnston, 1996); although, as noted above, some bicuculline-insensitive responses of GABA<sub>A</sub> receptors to CACA also have been observed in situ.

From the experience with other receptor classes, progress in obtaining and screening new series of GABA site agonists and antagonists can be expected to be a future important aid in the classification.

## VII. Conclusions

A classification can be erected for GABA<sub>A</sub> receptors (table 4) which accounts for their combinatorial multi-subunit structure; however, in the present state of our knowledge, its limitations are considerable. We have addressed the task of that classification from the broader perspective of the IUPHAR Committee on Receptor Nomenclature, in which it is important for progress in pharmacology to make a start on classifying all types of receptor, no matter how difficult this is initially. It can be argued that even the first stages of such classification will serve to order and systematize our existing knowledge of the receptor, bring uniformity to the terminology, and begin to allow rational distinctions between subtypes to be made in practical operations.

It is important to keep in mind, therefore, the special limitations that presently exist in a case such as that of the GABA<sub>A</sub> receptors:

1. It is very difficult to equate a subtype recognized from recombinant co-expression with an in vivo subtype. This arises from the complexity and inaccessibility of the CNS and from the co-occurrence of multiple subtypes of GABA receptors in small regions, or even on a single neuron. The most successful earlier classifications of other receptor types were possible because of the availability of accessible tissues with responses mediated by only one or a very few subtypes of a given receptor.
2. Many more receptor subtypes can (in this case but not in most others) be created in vitro than are likely to occur in vivo. Hence the classification cannot be based solely on the varieties of response that come from recombinant systems.
3. Many of the pharmacological observations are in fields such as psychopharmacology, neuropathology, anesthesia, etc., so that their interpretation in terms of molecular subtypes is far from direct. Further, the behavioral models used for testing (e.g.,

for anxiolytic effects) are intrinsically ambiguous, especially because of their control by multiple GABA-ergic circuits.

However, none of these constitutes an absolute limitation in principle. We can envisage, with the powerful advance of the technologies involved, the development of a high-resolution identification and pharmacology of native GABA<sub>A</sub> receptors, along with a comprehensive chemical exploitation of the sequence differences between each of the multisubunit structures. We regard this classification as a necessary preliminary stage in rationalizing the multiplicity of GABA<sub>A</sub> receptors.

*Acknowledgments.* John Alexander (Synthélabo Recherche, Paris) gave expert and invaluable help in assembling and checking the final version of our text and all of its references. IUPHAR is grateful to UNESCO for financial support toward the work of NC-IUPHAR.

## REFERENCES

- Akaike N, Rhee JS, Jin YH and Ono K (1996) Ontogenic changes of GABA<sub>A</sub> function of the rat Meynert neuron, in *GABA: Receptors, Transporters and Metabolism* (Tanaka C and Bowery NG eds) pp 201–202, Birkhauser, Basel.
- Angelotti TP and Macdonald RL (1993) Assembly of GABA<sub>A</sub> receptor subunits:  $\alpha_1\beta_1$  and  $\alpha_1\beta_1\gamma_2\alpha$  subunits produce unique ion channels with dissimilar single-channel properties. *J Neurosci* **13**:1429–1440.
- Arbilla S and Langer SZ (1986) [<sup>3</sup>H] Zolpidem: A novel non-benzodiazepine ligand with preferential affinity for the BZ<sub>1</sub> receptor subtype. *Br J Pharmacol* **87**:39P.
- Backus KH, Arigoni M, Drescher U, Scheurer L, Malherbe P, Mohler H and Benson JA (1993) Stoichiometry of a recombinant GABA<sub>A</sub>-receptor deduced from mutation-induced rectification. *Neuroreport* **5**:285–288.
- Barnard EA (1996a) The molecular biology of GABA<sub>A</sub> receptors and its application, in *GABA: Receptors, Transporters and Metabolism* (Tanaka C and Bowery NG eds) pp 129–144, Birkhauser, Basel.
- Barnard EA (1996b) The transmitter-gated channels: A range of receptor types and structures. *Trends Pharmacol Sci* **17**:305–308.
- Basile A, Klein D and Skolnick P (1986) Benzodiazepine receptors in the bovine pineal: Evidence for the presence of an “atypical” binding site. *Mol Brain Res* **1**:127–135.
- Basile A and Skolnick P (1986) Subcellular localization of “peripheral-type” binding sites for benzodiazepines in rat brain. *J Neurochem* **44**:305–308.
- Bateson AN, Lasham A and Darlison MG (1991) Gamma-aminobutyric acid-A receptor heterogeneity is increased by alternative splicing of a novel beta-subunit gene transcript. *J Neurochem* **56**:1437–1440.
- Bellelli D, Lambert JJ, Peters JA, Wafford K and Whiting PJ (1997) The interaction of the general anesthetic etomidate with the  $\gamma$ -aminobutyric acid type A receptor is influenced by a single amino acid. *Proc Natl Acad Sci USA* **94**:11031–11036.
- Ben-Ari Y, Khazipov R, Leinekugel X, Caillard O and Galarsa J-L (1997) GABA<sub>A</sub>, NMDA and AMPA receptors: A developmentally regulated “ménage à trois”. *Trends Neurosci* **20**:523–529.
- Benke D, Fritschy JM, Trzeciak A, Bannerworth W and Mohler H (1994) Distribution, prevalence and drug-binding profile of GABA<sub>A</sub>-receptor subtypes differing in  $\beta$ -subunit isoform. *J Biol Chem* **269**:27100–27107.
- Bleakman D, Ballyk BA, Schoepp DD, Palmer AJ, Bath CP, Sharpe EF, Woolley ML, Bufton HR, Kamboj RK, Tarnawa I and Lodge D (1996) Activity of 2,3-benzodiazepines at native rat and recombinant human glutamate receptors in vitro: Stereospecificity and selectivity profiles. *Neuropharmacology* **35**:1689–1702.
- Boess FG, Beroukhim R and Martin IL (1995) Ultrastructure of the 5-hydroxytryptamine<sub>3</sub> receptor. *J Neurochem* **64**:1401–1405.
- Bormann J and Feigenspan A (1995) GABA<sub>C</sub> receptors. *Trends Neurosci* **18**:515–519.
- Braestrup C, Schmiechen R, Neef G, Nielsen M and Petersen EN (1982) Interaction of convulsive ligands with benzodiazepine receptors. *Science (Wash. DC)* **216**:1241–1243.
- Braestrup C and Squires R (1977) Specific benzodiazepine receptors in rat brain characterized by high affinity [<sup>3</sup>H]diazepam binding. *Proc Natl Acad Sci USA* **74**:3804–3809.
- Buckle VJ, Fujita N, Ryder-Cook AS, Derry JM, Barnard PJ, Lebo RV, Schofield PR, Seeburg PH, Bateson AN, Darlison MG and Barnard EA (1989) Chromosomal localization of GABA<sub>A</sub> receptor subunit genes: Relationship to human genetic diseases. *Neuron* **3**:647–654.
- Burgard EC, Tietz EI, Neelands TR and Macdonald RL (1996) Properties of recombinant  $\gamma$ -aminobutyric acid A receptor isoforms contain the  $\alpha_5$  subunit type. *Mol Pharmacol* **50**:119–127.
- Burt DR and Kamatchi GL (1991) GABA<sub>A</sub> receptor subtypes: From pharmacology to molecular biology. *FASEB J* **5**:2916–2923.
- Caruncho HJ and Costa E (1994) Double-immunolabeling analysis of GABA<sub>A</sub> receptor subunits in label fracture replicas of cultured cerebellar granule cells. *Receptors Channels* **2**:143–153.
- Chang L-R, Barnard EA, Lo MMS and Dolly JO (1981) Molecular sizes of benzodiazepine receptors and the interacting GABA receptors in the membrane are identical. *FEBS Lett* **126**:309–312.

- Chang Y, Wang R, Barot S and Weiss DS (1996) Stoichiometry of a recombinant GABA<sub>A</sub> receptor. *J Neurosci* **16**:5415–5424.
- Cherubini E, Giarsa JL and Ben-Ari Y (1991) GABA, an excitatory transmitter in early postnatal life. *Trends Neurosci* **14**:515–519.
- Corda MG, Giorgi O, Longoni B, Ongini E, Montaldo S and Biggio G (1988) Preferential affinity of <sup>3</sup>H-2-oxo-quazepam for type I benzodiazepine recognition sites in the human brain. *Life Sci* **42**:189–197.
- Costa E, Guidotti A and Mao CC (1975) Evidence for the involvement of GABA in the action of benzodiazepines. *Adv Biochem Psychopharmacol* **14**:113–130.
- Cutting GR, Curristin S, Zoghbi H, O'Hara B, Seldin MF and Uhl GR (1992) Identification of a putative  $\gamma$ -aminobutyric acid (GABA) receptor rho2 cDNA and colocalization of the genes encoding rho2 (GABRR2) and rho1 (GABRR1) to human chromosome 6q14–q21 and mouse chromosome 4. *Genomics* **12**:801–806.
- Cutting GR, Lu L, O'Hara BF, Kasch LM, Montrose Rafizadeh C, Donovan DM, Shimada S, Antonarakis SE, Guggino WB, Uhl GR and Kazazian HH Jr (1991) Cloning of the  $\gamma$ -aminobutyric acid (GABA) rho, cDNA: A GABA receptor subunit highly expressed in the retina. *Proc Natl Acad Sci USA* **88**:2673–2677.
- Davies PA, Hanna MC, Hales TG and Kirkness EF (1997) A novel class of GABA-A receptor subunit confers insensitivity to anaesthetic agents. *Nature (Lond.)* **385**:820–823.
- Drew CA, Johnston GAR and Weatherby RP (1984) Bicuculline-insensitive GABA receptors: Studies on the binding of (-)-baclofen to rat cerebellar membranes. *Neurosci Lett* **52**:317–321.
- Ducic I, Caruncho HJ, Zhu WJ, Vicini S and Costa E (1995)  $\gamma$ -Aminobutyric acid gating of Cl<sup>-</sup> channels in recombinant GABA<sub>A</sub> receptors. *J Pharmacol Exp Ther* **272**:438–445.
- Duggan MJ, Pollard S and Stephenson FA (1991) Immunoaffinity purification of GABA<sub>A</sub> receptor  $\alpha$ -subunit iso-oligomers: Demonstration of receptor populations containing  $\alpha_1\alpha_2$ ,  $\alpha_1\alpha_3$  and  $\alpha_2\alpha_3$  subunit pairs. *J Biol Chem* **266**:24778–24784.
- Ebert B, Wafford KA, Whiting PJ, Krosggaard-Larsen P and Kemp JA (1994) Molecular pharmacology of a  $\gamma$ -aminobutyric acid type A receptor agonists and partial agonists in oocytes injected with different  $\alpha$ ,  $\beta$ , and  $\gamma$  receptor subunit combinations. *Mol Pharmacol* **46**:957–963.
- Eghbali M, Curmi JP, Birnir B and Gage PW (1997) Hippocampal GABA<sub>A</sub> channel conductance increased by diazepam. *Nature (Lond.)* **388**:71–75.
- Endo S and Olsen RW (1993) Antibodies specific for  $\alpha$  subunit subtypes of GABA<sub>A</sub> receptors reveal brain regional heterogeneity. *J Neurochem* **60**:1388–1398.
- Enna SJ and Bowers NG (1997) *The GABA Receptors*. Humana Press, Totowa, NJ.
- Enz R, Brandstatter JH, Hartveit E, Wassle H and Bormann J (1995) Expression of GABA receptor  $\rho_1$  and  $\rho_2$  subunits in the retina and brain of the rat. *Eur J Neurosci* **7**:1495–1501.
- Faure-Halley C, Graham D, Arbilla S and Langer SZ (1993) Expression and properties of recombinant  $\alpha_1\beta_2\gamma_2$  and  $\alpha_5\beta_2\gamma_2$  forms of the rat GABA<sub>A</sub> receptor. *Eur J Pharmacol* **246**:283–287.
- Feigenspan A, Wassle H and Bormann J (1993) Pharmacology of the GABA receptor Cl<sup>-</sup> channel in rat retina bipolar cells. *Nature (Lond.)* **361**:159–162.
- Fredholm BB, Abbracchio MP, Burnstock G, Daly JW, Harden TK, Jacobson KA, Leff P and Williams M (1994) Nomenclature and classification of purinoceptors. *Pharmacol Rev* **46**:143–156.
- Fritschy JM, Benke D, Mertens S, Oertel WH, Bachi T and Mohler H (1992) Five subtypes of type A  $\gamma$ -aminobutyric acid receptors identified in neurons by double and triple immunofluorescence staining with subunit-specific antibodies. *Proc Natl Acad Sci USA* **89**:6726–6730.
- Giusti P, Ducic I, Puia G, Arban R, Walser A, Guidotti A and Costa E (1993) Imidazenil: A new partial positive allosteric modulator of gamma-aminobutyric acid (GABA) action at GABA<sub>A</sub> receptors. *J Pharmacol Exp Ther* **266**:1018–1028.
- Glatt K, Glatt H and Lalande M (1997) Structure and organization of GABRB3 and GABRA5. *Genomics* **41**:63–69.
- Glencorse TA, Bateson AN and Darlison MG (1992) Differential localization of two alternatively spliced GABA<sub>A</sub> receptor  $\gamma_2$ -subunit mRNAs in the chick brain. *Eur J Neurosci* **4**:271–277.
- Gregor V, Knoll JHM, Woolf E, Glatt K, Tyndale RF, Delorey TM, Olsen RW, Tobin AJ, Sikela JM, Nakatsu Y, Brilliant MH, Whiting PJ and Lalande M (1995) The  $\gamma$ -aminobutyric acid receptor  $\gamma_3$  subunit gene (GABRG3) is tightly linked to the  $\alpha_5$  subunit gene (GABRA5) on human chromosome 15q11–q13 and is transcribed in the same orientation. *Genomics* **26**:258–264.
- Günther U, Benson JA, Benke D, Fritschy J-M, Reyes G, Knoflach F, Crestani F, Aguzzi A, Arigoni M, Lang Y, Bluethmann H, Mohler H and Luscher B (1995) Benzodiazepine-insensitive mice generated by targeted disruption of the  $\gamma_2$  subunit gene of  $\gamma$ -aminobutyric acid type A receptors. *Proc Natl Acad Sci USA* **92**:7749–7753.
- Hadingham KL, Garrett EM, Wafford KA, Bain C, Heavens RP, Sirinathsinghi DS and Whiting PJ (1996) Cloning of cDNA encoding the human  $\gamma$ -aminobutyric acid<sub>A</sub> receptor  $\alpha_6$  subunit and characterization of the pharmacology of  $\alpha_6$ -containing receptors. *Mol Pharmacol* **49**:253–259.
- Hadingham KL, Wafford KA, Thompson SA, Palmer KJ and Whiting PJ (1995) Expression and pharmacology of human GABA<sub>A</sub> receptors containing  $\gamma_3$  subunits. *Eur J Pharmacol* **291**:301–309.
- Hadingham KL, Wingrove P, Le Bourdelles B, Palmer KJ, Ragan CI and Whiting PJ (1993) Cloning of cDNA sequences encoding human  $\alpha_2$  and  $\alpha_3$   $\gamma$ -aminobutyric acid A receptor subunits and characterization of the benzodiazepine pharmacology of recombinant  $\alpha_1$ -,  $\alpha_2$ -,  $\alpha_3$ -, and  $\alpha_5$ -containing human  $\gamma$ -aminobutyric acid<sub>A</sub> receptors. *Mol Pharmacol* **43**:970–975.
- Haefely W, Kuscar A, Mohler H, Pieri L, Polc P and Schaffner R (1975) Possible involvement of GABA in the central actions of benzodiazepines. *Adv Biochem Psychopharmacol* **14**:131–151.
- Haefely W, Kyburz E, Gerecke M and Mohler H (1985) Recent advances in the molecular pharmacology of benzodiazepine receptors and in the structure-activity relationships of their agonists and antagonists, in *Advances In Drug Research* (Testa B ed) vol. 14, pp 165–322, Academic Press, London.
- Haefely WE (1989) Pharmacology of the allosteric modulation of GABA<sub>A</sub> receptors by benzodiazepine receptor ligands, in *Allosteric Modulation of Amino Acid Receptors: Therapeutic Implications* (Barnard EA and Costa E, eds) pp 47–69, Raven Press, New York.
- Harvey RJ, Chinchetru MA and Darlison MGD (1994) Alternative splicing of a 51-nucleotide exon that encodes a putative protein kinase C phosphorylation site generates two forms of the chicken  $\gamma$ -aminobutyric acid<sub>A</sub> receptor  $\beta_2$  subunit. *J Neurochem* **62**:10–16.
- Harvey RJ, Kim HC and Darlison MG (1993) Molecular cloning reveals the existence of a fourth gamma subunit of the vertebrate brain GABA<sub>A</sub> receptor. *FEBS Lett* **331**:211–216.
- Heaulme M, Chambon JP, Leyris R, Wermuth CG and Biziere K (1987) Characterization of the binding of [<sup>3</sup>H] SR 95531, a GABA antagonist, to rat brain membranes. *J Neurochem* **48**:1677–1686.
- Heblom E and Kirkness EF (1997) A novel class of GABA<sub>A</sub> receptor subunit in tissues of the reproductive system. *J Biol Chem* **272**:15346–15350.
- Herb A, Wisden W, Luddens H, Puia G, Vicini S and Seeburg PH (1992) The third  $\gamma$ -subunit of the  $\gamma$ -aminobutyric acid type A receptor family. *Proc Natl Acad Sci USA* **89**:1433–1437.
- Hicks AA, Bailey MES, Riley BP, Kamphuis W, Siciliano MJ, Johnson KJ and Darlison MG (1994) Further evidence for clustering of human GABA<sub>A</sub> receptor subunit genes: Localization of the  $\alpha_6$ -subunit gene (GABRA6) to distal chromosome 5q by linkage analysis. *Genomics* **20**:285–288.
- Hill DR and Bowers NG (1981) <sup>3</sup>H-baclofen and <sup>3</sup>H-GABA bind to bicuculline-insensitive GABA<sub>B</sub> sites in rat brain. *Nature (Lond.)* **290**:149–152.
- Horvath EJ, Palkovits M, Lenkei Z, Gyure KI, Fekete MI and Aranyi P (1994) Autoradiographic localization and quantitative determination of specific binding sites of anxiolytic homophthalazines (formerly called 2,3-benzodiazepines) in the striato-pallido-nigral system of rats. *Mol Brain Res* **22**:211–218.
- Hoyer D, Clarke DE, Fozard JR, Hartig PR, Martin GR, Mylecharane EJ, Saxena PR and Humphrey PP (1994) A classification of receptors for 5-hydroxytryptamine (serotonin). *Pharmacol Rev* **46**:157–203.
- Huh KH, Endo S and Olsen WO (1996) Diazepam-insensitive GABA<sub>A</sub> receptors in rat cerebellum and thalamus. *Eur J Pharmacol* **310**:225–233.
- Im HK, Im WB, Judge TM, Gammill RB, Hamilton BJ, Carter DB and Pregenzer JF (1993a) Substituted pyrazinones, a new class of allosteric modulators for  $\gamma$ -aminobutyric acid<sub>A</sub> receptors. *Mol Pharmacol* **44**:468–472.
- Im WB, Im HK, Pregenzer JF, Hamilton BJ, Carter DB, Jacobsen EJ, Tenbrink RE and Von Voiglander PF (1993b) Differential affinity of dihydroimidazoquinoxalines and diimidazoquinazolines to the  $\alpha_1\beta_2\gamma_2$  and  $\alpha_6\beta_2\gamma_2$  subtypes of cloned GABA<sub>A</sub> receptors. *Br J Pharmacol* **110**:677–680.
- Im WB, Pregenzer JF, Binder JA, Dillon GH and Alberts GL (1995) Chloride channel expression with the tandem construct of  $\alpha_6\beta_2$  GABA<sub>A</sub> receptor subunit requires a monomeric subunit of  $\alpha_6$  or  $\gamma_2$ . *J Biol Chem* **270**:26063–26066.
- Inglefield JR and Schwartz-Bloom RD (1996) Confocal imaging of intracellular chloride (Cl<sup>-</sup>) in acutely prepared slices: Measurement of GABA<sub>A</sub> receptor activity. *Soc Neurosci Abstr* **22**:815.
- Iorio LC, Barnett A and Billard W (1984) Selective affinity of 1-N-trifluoroethyl benzodiazepines for cerebellar type I receptor sites. *Life Sci* **35**:105–113.
- Jechlinger M, Pelz R, Tretter V, Klausberger T and Sieghart W (1998) Subunit composition and quantitative importance of hetero-oligomeric receptors: GABA<sub>A</sub> receptors containing  $\alpha_6$  subunits. *J Neurosci* **18**:2449–2457.
- Johnston GAR (1996) GABA<sub>C</sub> receptors: relatively simple transmitter-gated ion channels? *Trends Pharmacol Sci* **17**:319–323.
- Jones A, Korpi ER, McKernan RM, Pelz R, Nusser Z, Mäkelä R, Mellor JR, Pollard S, Bahn S, Stephenson FA, Randall AD, Sieghart W, Somogyi P, Smith AJH and Wisden W (1997) Ligand-gated ion channel subunit partnerships: GABA<sub>A</sub> receptor  $\alpha_6$  subunit gene inactivation inhibits  $\delta$  subunit expression. *J Neurosci* **17**:1350–1362.
- Kaila K, Lamsa K, Smirnov S, Taira T and Voipio J (1997) Long-lasting GABA-mediated depolarization evoked by high-frequency stimulation in pyramidal neurons of rat hippocampal slice is attributable to a network-driven, bicarbonate-dependent K<sup>+</sup> transient. *J Neurosci* **17**:7662–7672.
- Karlin A (1991) Explorations of the nicotinic-acetylcholine receptor. *Harvey Lect* **85**:71–107.
- Kaupmann K, Huggel K, Heid J, Flor PJ, Bischoff S, Mickel SJ, McMastar G, Angst C, Bittiger H, Froesti W and Bettler R (1997) Expression cloning of GABA<sub>B</sub> receptors uncovers similarity to metabotropic glutamate receptors. *Nature (Lond.)* **386**:239–246.
- Kenakin TP, Bond RA and Bonner TI (1992) Definition of pharmacological receptors. *Pharmacol Rev* **44**:351–362.
- Khan ZU, Gutierrez A and De Blas AL (1994a) Short and long form  $\gamma_2$  subunits of GABA/benzodiazepine receptor from rat cerebellum. *J Neurochem* **63**:1466–1476.
- Khan ZU, Gutierrez A and De Blas AL (1994b) The subunit composition of a GABA<sub>A</sub>/benzodiazepine receptor from rat cerebellum. *J Neurochem* **63**:371–374.
- Khan ZU, Gutierrez A and De Blas AL (1996) The  $\alpha_1$  and  $\alpha_6$  subunits can co-exist in the same cerebellar GABA<sub>A</sub> receptor maintaining their individual benzodiazepine-binding affinities. *J Neurochem* **66**:685–691.
- Kim Y, Glatt H, Xie W, Sinnott D and Lalande M (1997) Human gammaaminobutyric acid-type A receptor alpha 5 subunit gene (GABRA5): characterization and structural organization of the 5' flanking region. *Genomics* **42**:378–387.
- Kirkness EF and Fraser CM (1993) A strong promoter element is located between alternative exons of a gene encoding the human  $\gamma$ -aminobutyric acid-type A receptor  $\beta_2$  subunit (GABRB3). *J Biol Chem* **268**:4420–4428.
- Kirsch T, Kuhse I and Betz H (1995) Targeting of glycine receptor subunits to gephyrin-rich domains in transfected human embryonic kidney cells. *Mol Cell Neurosci* **6**:450–462.
- Kleingoor C, Ewert M, Von Blankenfeld G, Seeburg PH and Kettermann H (1991) Inverse but not full benzodiazepine agonists modulate recombinant  $\alpha_6\beta_2\gamma_2$  GABA<sub>A</sub> receptors in transfected human embryonic kidney cells. *Neurosci Lett* **130**:169–172.
- Knoflach F, Benke D, Wang Y, Scheurer L, Luddens H, Hamilton BJ, Carter DB,

- Mohler H and Benson JA (1996) Pharmacological modulation of the diazepam-insensitive recombinant  $\gamma$ -aminobutyric acid A receptors  $\alpha_4\beta_2\gamma_2$  and  $\alpha_6\beta_2\gamma_2$ . *Mol Pharmacol* **50**:1243–1261.
- Knoll JH, Sinnert D, Wagstaff J, Glatt K, Wilcox AS, Whiting PM, Wingrove P, Sikela JM and Lalonde M (1993) FISH ordering of reference markers and of the gene for the  $\alpha_5$  subunit of the gamma-aminobutyric acid receptor (GABRA5) within the Angelman and Prader-Willi syndrome chromosomal regions. *Hum Mol Genet* **2**:183–189.
- Kofuji P, Wang JB, Moss SJ, Hagan RL and Burt DR (1991) Generation of two forms of the gamma-aminobutyric acid-A receptor gamma-2-subunit in mice by alternative splicing. *J Neurochem* **56**:713–715.
- Korpi ER, Kuner T, Kristo P, Kohcer M, Herb A, Luddens H and Seeburg PHT (1994) Small N-terminal deletion by splicing in cerebellar  $\alpha_6$  - subunit abolishes GABA<sub>A</sub> receptor function. *J Neurochem* **63**:1167–1170.
- Korpi ER, Kuner T, Seeburg PH and Luddens H (1995) Selective antagonist for the cerebellar granule cell - specific  $\gamma$  - aminobutyric acid type A receptor. *Mol Pharmacol* **47**:283–289.
- Koulen P, Brandstätter JH, Enz R, Bormann J and Wässle H (1998) Synaptic clustering of GABA<sub>C</sub> receptor  $\rho$ -subunits in the rat retina. *Eur J Neurosci* **10**:115–127.
- Krishek BJ, Amato A, Connolly CN, Moss SJ and Smart TG (1996) Proton sensitivity of the GABA<sub>A</sub> receptor is associated with the receptor subunit composition. *J Physiol (Lond.)* **492**:431–443.
- Kusama T, Spivak CE, Whiting P, Dawson VL, Schaeffer JC and Uhl GR (1993a) Pharmacology of GABA $\rho_1$  and GABA $\rho_2$  receptors expressed in *Xenopus* oocytes and Cos cells. *Br J Pharmacol* **109**:200–206.
- Kusama T, Wang TL, Guggino WB, Cutting GR and Uhl GR (1993b) GABA rho 2 receptor pharmacological profile: GABA recognition site similarities to rho 1. *Eur J Pharmacol* **245**:83–84.
- Langer SZ and Arbilla S (1988) Imidazopyridines as a tool for the characterization of benzodiazepine receptors: A proposal for pharmacological classification as omega receptors. *Pharmacol Biochem Behav* **29**:763–766.
- Laurie DJ, Seeburg PH and Wisden W (1992) The distribution of 13 GABA<sub>A</sub> receptor subunit mRNAs in the rat brain. II. Olfactory bulb and cerebellum. *J Neurosci* **12**:1063–1076.
- Leeb-Lundberg LM and Olsen RW (1983) Heterogeneity of benzodiazepine receptor interactions with  $\gamma$ -aminobutyric acid and barbiturate receptor sites. *Mol Pharmacol* **23**:315–325.
- Levin ML, Chatterjee A, Pragliola A, Worley KC, Wehnert M, Zhuchenko O, Smith RF, Lee CC and Herman GE (1996) A comparative transcription map of the murine bare patches (Bpa) and striated (Str) critical regions and human Xq28. *Genome Res* **6**:465–477.
- Li M and De Blas AL (1997) Coexistence of two  $\beta$  subunit isoforms in the same  $\gamma$ -aminobutyric acid type A receptor. *J Biol Chem* **272**:16564–16569.
- Lippa AS, Beer B, Sano MC, Vogel RA and Meyerson LR (1981) Differential ontogeny of type 1 and 2 benzodiazepine receptors. *Life Sci* **28**:2343–2347.
- Liu R, Hu RJ, Zhang P, Skolnick P and Cook JM (1996) Synthesis and pharmacological properties of novel  $\gamma$ -substituted imidazobenzodiazepines: high-affinity, selected probes for  $\alpha_5$ -containing GABA<sub>A</sub> receptors. *J Med Chem* **39**:1928–1934.
- Luddens H, Killisch I and Seeburg PH (1991) More than one alpha variant may exist in a GABA<sub>A</sub> benzodiazepine receptor complex. *J Recept Res* **11**:535–551.
- Luddens H, Pritchett DB, Kohler M, Killisch L, Keinan K, Monyer H, Sprengel R and Seeburg PH (1990) Cerebellar GABA<sub>A</sub> receptor selective for a behavioural alcohol antagonist. *Nature (Lond.)* **346**:648–651.
- Luddens H, Seeburg PH and Korpi ER (1994) Impact of  $\alpha$  and  $\gamma$  variants on ligand-binding properties of  $\gamma$ -aminobutyric acid type A receptors. *Mol Pharmacol* **45**:810–814.
- Lukasiewicz PD (1996) GABA<sub>C</sub> receptors in the vertebrate retina. *Mol Neurobiol* **12**:181–194.
- Macdonald RL and Olsen RW (1994) GABA<sub>A</sub> receptor channels. *Annu Rev Neurosci* **17**:569–602.
- Mäkelä R, Uusi-Oukari M, Homanics GE, Quinlan JJ, Firestone LL, Wisden W and Korpi ER (1997) Cerebellar  $\gamma$ -aminobutyric acid type A receptors: Pharmacological subtypes revealed by mutant mouse lines. *Mol Pharmacol* **52**:380–388.
- Mamalaki C, Barnard EA and Stephenson FA (1989) Molecular size of the  $\gamma$ -aminobutyric acid<sub>A</sub> receptor purified from mammalian cerebral cortex. *J Neurochem* **52**:125–134.
- McKernan RM and Whiting PJ (1996) Which GABA<sub>A</sub>-receptor subtypes really occur in the brain? *Trends Neurosci* **19**:139–143.
- McLean PJ, Farb DH and Russek SJ (1995) Mapping of the  $\alpha_4$  subunit gene (GABRA4) to human chromosome 4 defines an  $\alpha_2$ - $\alpha_4$ - $\beta_1$ - $\gamma_1$  gene cluster: Further evidence that modern GABA<sub>A</sub> receptor gene clusters are derived from an ancestral gene cluster. *Genomics* **26**:580–586.
- Melikian A, Schlexer G, Chambon JP and Wermuth CG (1992) Condensation of muscimol or thiomuscimol with aminopyridazines yields GABA<sub>A</sub> antagonists. *J Med Chem* **35**:4092–4097.
- Mertens S, Benke D and Mohler H (1993) GABA<sub>A</sub> receptor populations with novel subunit combinations and drug binding profiles identified in brain by  $\alpha_5$ - and  $\delta$ -subunit-specific immunoprecipitation. *J Biol Chem* **268**:5965–5973.
- Mohler H, Battersby MK and Richards JG (1980) Benzodiazepine receptor protein identified and visualized in brain tissue by a photoaffinity label. *Proc Natl Acad Sci USA* **77**:1666–1670.
- Mohler H, Fritschy JM, Benke D, Rudolph U and Lüscher B (1996a) GABA<sub>A</sub> receptor subtypes: Pharmacological significance and mutational analysis in vivo, in *GABA: Receptors, Transporters and Metabolism* (Tanaka C and Bowery NG, eds) pp 157–171, Birkhäuser, Basel.
- Mohler H, Fritschy JM, Lüscher B, Rudolph U and Benson J (1996b) The GABA<sub>A</sub>-receptors: From subunits to diverse functions, in *Ion Channels* (Narahashi T ed) vol 4, pp 89–113, Plenum Press, New York.
- Mohler H and Okada T (1977) Benzodiazepine receptors: Demonstration in the central nervous system. *Science (Wash. DC)* **198**:849–851.
- Mohler H and Richards JG (1981) Agonist and antagonist benzodiazepine receptor interaction in vitro. *Nature (Lond.)* **294**:763–765.
- Mossier B, Tögel M, Fuchs K and Sieghart W (1994) Immunoaffinity purification of  $\gamma$ -aminobutyric acid<sub>A</sub> (GABA<sub>A</sub>) receptors containing  $\gamma$ 1-subunits: Evidence for the presence of a single type of  $\gamma$ -subunit in GABA<sub>A</sub> receptors. *J Biol Chem* **269**:25777–25782.
- Nayem N, Green TP, Martin IL and Barnard EA (1994) Quaternary structure of the native GABA<sub>A</sub> receptor determined by electron microscope image analysis. *J Neurochem* **62**:815–818.
- Nielsen H, Engelbrecht J, Brunak S and Von Heijne G (1997) Identification of prokaryotic and eukaryotic signal peptides and prediction of their cleavage sites. *Protein Eng* **10**:1–6.
- North RA and Barnard EA (1997) Nucleotide receptors. *Curr Opin Neurobiol* **7**:346–357.
- Nusser Z, Sieghart W, Stephenson FA and Somogyi P (1996) The  $\alpha_6$  subunit of the GABA<sub>A</sub> receptor is concentrated in both inhibitory and excitatory synapses on cerebellar granule cells. *J Neurosci* **16**:103–114.
- Ogurusu T, Eguchi G and Shingai R (1997) Localization of  $\gamma$ -aminobutyric acid (GABA) receptor  $\rho$ 3 subunit in rat retina. *Neuroreport* **8**:925–927.
- Ogurusu T and Shingai R (1996) Cloning of a putative  $\gamma$ -aminobutyric acid (GABA) receptor subunit rho3 cDNA. *Biochim Biophys Acta* **1305**:15–18.
- Ogurusu T, Taira H and Shingai R (1995) Identification of GABA<sub>A</sub> receptor subunits in rat retina: Cloning of the rat GABA<sub>A</sub> receptor  $\rho$  2-subunit cDNA. *J Neurochem* **65**:964–968.
- Olsen RW (1981) GABA-benzodiazepine-barbiturate receptor interactions. *J Neurochem* **37**:1–13.
- Olsen RW, McCabe RT and Wamsley JK (1990) GABA<sub>A</sub> receptor subtypes: Autoradiographic comparison of GABA, benzodiazepine and convulsant binding sites in the rat central nervous system. *J Chem Neuroanat* **3**:59–76.
- Olsen RW, Smith GB and Srinivasan S (1996) Modelling functional domains of the GABA<sub>A</sub> receptor chloride channel protein, in *GABA: Receptors, Transporters and Metabolism* (Tanaka C and Bowery NG eds) pp 145–155, Birkhäuser, Basel.
- Pan Z-H, Zhang X, Zhang Z and Lipton SA (1997) Evidence for co-assembly of GABA $\rho_1$  with GABA<sub>A</sub> or glycine subunits in vitro. *Soc Neurosci Abstr* **7**:6.
- Paul S, Marangos P and Skolnick P (1981) The benzodiazepine-GABA-chloride-ionophore receptor complex: Common site of minor tranquilizer action. *Biol Psychiatry* **16**:213–229.
- Perkins KL and Wong RKS (1996) Ionic basis of the postsynaptic depolarizing GABA response in hippocampal pyramidal cells. *J Neurophysiol* **76**:3886–3894.
- Perriere G and Gouy M (1996) WWW-Query: An on-line retrieval system for biological sequence banks. *Biochimie* **78**:364–369.
- Polc P, Bonetti EO, Schaffner R and Haefely W (1982) A three-state model of the benzodiazepine receptor explains the interactions between the benzodiazepine antagonist Ro 15–1788, benzodiazepine tranquilizers,  $\beta$ -carbolines and phenobarbitone. *Naunyn Schmiedebergs Arch Pharmacol* **321**:260–264.
- Polenzani L, Woodward RM and Miledi R (1991) Expression of mammalian  $\gamma$ -aminobutyric acid receptors with distinct pharmacology in *Xenopus* oocytes. *Proc Natl Acad Sci USA* **88**:4318–4322.
- Pollard S, Duggan MJ and Stephenson FA (1993) Further evidence for the existence of a subunit heterogeneity within discrete  $\gamma$ -aminobutyric acid<sub>A</sub> receptor subpopulations. *J Biol Chem* **268**:3753–3757.
- Pollard S, Thompson CL and Stephenson FA (1995) Quantitative characterization of  $\alpha_6$  and  $\alpha_1\alpha_6$  subunit-containing native GABA<sub>A</sub> receptors of adult rat cerebellum demonstrates 2 $\alpha$  subunits per receptor oligomer. *J Biol Chem* **270**:21285–21292.
- Pritchett DB and Seeburg PH (1990)  $\gamma$ -aminobutyric acid<sub>A</sub> receptor  $\alpha_5$  - subunit creates novel type II benzodiazepine receptor pharmacology. *J Neurochem* **54**:1802–1804.
- Puia G, Vicini S, Seeburg PH and Costa E (1991) Influence of recombinant  $\gamma$ -aminobutyric acid-A receptor subunit composition on the action of allosteric modulators of  $\gamma$ -aminobutyric acid-gated Cl<sup>-</sup> currents. *Mol Pharmacol* **39**:691–696.
- Quian H and Dowling JE (1993) Novel GABA responses from rod-driven retinal horizontal cells. *Nature (Lond.)* **361**:162–164.
- Quirk K, Blurton P, Fletcher S, Leeson P, Tang F, Mellilo D, Ragan CI and McKernan RM (1996) [<sup>3</sup>H]-L-655,708, a novel ligand selective for the benzodiazepine site of GABA<sub>A</sub> receptors which contain the  $\alpha_5$  subunit. *Neuropharmacology* **35**:1331–1335.
- Quirk K, Gillard NP, Ragan CI, Whiting PJ and McKernan RM (1994a)  $\gamma$ -Aminobutyric acid type A receptors in the rat brain can contain both  $\gamma_2$  and  $\gamma_3$  subunits, but  $\gamma_1$  does not exist in combination with another  $\gamma$  subunit. *Mol Pharmacol* **45**:1061–1070.
- Quirk K, Gillard NP, Ragan CI, Whiting PJ and McKernan RM (1994b)  $\gamma$ -Aminobutyric acid type A receptor subtypes expressed in rat cerebellum with respect to their  $\alpha$  and  $\gamma/\delta$  subunits. *J Biol Chem* **269**:16020–16028.
- Quirk K, Whiting PJ, Ragan CI and McKernan RM (1995) Characterisation of delta-subunit containing GABA<sub>A</sub> receptors from rat brain. *Eur J Pharmacol* **290**:175–181.
- Rogers CJ, Twyman RE and MacDonald RL (1994) Benzodiazepine and beta-carboline regulation of single GABA<sub>A</sub>-receptor channels of mouse spinal neurons in culture. *J Physiol (Lond.)* **475**:69–82.
- Rovira C and Ben-Ari Y (1991) Benzodiazepines do not potentiate GABA responses in neonatal hippocampal neurons. *Neurosci Lett* **130**:157–161.
- Russek SJ and Farb DH (1994) Mapping of the  $\beta_2$  subunit gene (GABRB2) to microdissected human chromosome 5q34–q35 defines a gene cluster for the most abundant GABA<sub>A</sub> receptor isoform. *Genomics* **23**:528–533.
- Santi MR, Vincini S, Eldalah B and Neale JH (1994) Analysis by polymerase chain reaction of alpha 1 and alpha 6 GABA<sub>A</sub> receptor subunit mRNAs in individual cerebellar neurons after whole-cell recordings. *J Neurochem* **63**:2357–2360.
- Sato K, Momose-Sato Y, Hirota A, Sakai T and Kamino K (1996) Optical studies of the biphasic modulatory effects of glycine on excitatory postsynaptic potentials in the chick brainstem and their embryogenesis. *Neuroscience* **72**:833–846.

- Saxena NC and MacDonald RL (1994) Assembly of GABA<sub>A</sub> receptor subunits: role of the  $\delta$ -subunit. *J Neurosci* **14**:7077–7086.
- Saxena NC and MacDonald RL (1996) Properties of putative cerebellar  $\gamma$ -aminobutyric acid A receptor isoforms. *Mol Pharmacol* **49**:567–579.
- Schofield PR, Darlison MG, Fujita N, Burt DR, Stephenson FA, Rodriguez H, Rhee LM, Ramachandran J, Reale V, Glencorse TA, Seeburg PH and Barnard EA (1987) Sequence and functional expression of the GABA<sub>A</sub> receptor shows a ligand-gated receptor superfamily. *Nature (Lond.)* **328**:221–227.
- Scholze P, Ebert V and Sieghart W (1996) Affinity of ligands for GABA<sub>A</sub> receptors containing  $\alpha_4 \beta_3 \gamma_2$ ,  $\alpha_4 \gamma_2$  or  $\alpha_1 \beta_3 \gamma_2$  subunits. *Eur J Pharmacol* **304**:155–162.
- Shimada S, Cutting GR and Uhl GR (1992)  $\gamma$ -Aminobutyric acid A or C receptor?  $\gamma$ -aminobutyric acid  $\rho_1$  receptor RNA induces bicuculline-, barbiturate-, and benzodiazepine-insensitive  $\gamma$ -aminobutyric acid responses in *Xenopus* oocytes. *Mol Pharmacol* **41**:683–687.
- Shingai R, Yanagi K, Fukushima T, Sakata K and Ogurusu T (1996) Functional expression of rat GABA receptor  $\rho_3$  subunit. *Neurosci Res* **26**:337–390.
- Sieghart W (1995) Structure and pharmacology of gamma-aminobutyric acid<sub>A</sub> receptor subtypes. *Pharmacol Rev* **47**:181–234.
- Sieghart W and Schuster A (1984) Affinity of various ligands for benzodiazepine receptors in rat cerebellum and hippocampus. *Biochem Pharmacol* **33**:4033–4038.
- Sigel E and Barnard EA (1984) A  $\gamma$ -aminobutyric acid/benzodiazepine receptor complex from bovine cerebral cortex: Improved purification with preservation of regulatory sites and their regulations. *J Biol Chem* **259**:7129–7223.
- Sivillotti L and Nistri A (1991) GABA receptor mechanisms in the central nervous system. *Prog Neurobiol* **36**:35–92.
- Smith GB and Olsen RW (1995) Functional domains of GABA<sub>A</sub> receptors. *Trends Pharmacol Sci* **16**:162–168.
- Sommer B, Poustka A, Spurr NK and Seeburg PH (1990) The murine GABA<sub>A</sub> receptor  $\delta$ -subunit gene: Structure and assignment to human chromosome 1. *DNA Cell Biol* **9**:561–568.
- Staley KJ, Soldo BL and Proctor WR (1995) Ionic mechanisms of neuronal excitation by inhibitory GABA<sub>A</sub> receptors. *Science (Wash. DC)* **269**:977–981.
- Stephenson FA (1995) The GABA<sub>A</sub> receptors. *Biochem J* **310**:1–9.
- Strata F and Cherubini E (1994) Transient expression of a novel type of GABA response in rat CA<sub>3</sub> hippocampal neurones during development. *J Physiol (Lond.)* **480**:493–503.
- Tanaka C and Bowerly NG (1996) *GABA: Receptors, Transporters and Metabolism*, Birkhauser, Basel.
- Thompson CL, Bodewitz G, Stephenson FA and Turner JD (1992) Mapping of GABA<sub>A</sub> receptor  $\alpha_6$  and  $\alpha_6$  subunit-like immunoreactivity in rat brain. *Neurosci Lett* **144**:53–56.
- Thompson JD, Higgins DG and Gibson TJ (1994) CLUSTAL W: Improving the sensitivity of progressive multiple sequence alignment through sequence weighting, positions-specific gap penalties and weight matrix choice. *Nucleic Acids Res* **22**:4673–4680.
- Tomiko SA, Taraskevich PS and Douglas WW (1983) GABA acts directly on cells of pituitary pars intermedia. *Nature (Lond.)* **301**:706–707.
- Toyoshima C and Unwin N (1988) Ion channel of acetylcholine receptor reconstructed from images of postsynaptic membranes. *Nature (Lond.)* **336**:247–250.
- Tretter V, Ehya N, Fuchs K and Sieghart W (1997) Stoichiometry and assembly of a recombinant GABA<sub>A</sub> receptor subtype. *J Neurosci* **17**:2728–2737.
- Unnerstall JR, Kuhar MJ, Niehoff DL and Palacios JM (1981) Benzodiazepine receptors are coupled to a subpopulation of  $\gamma$ -aminobutyric acid (GABA) receptors: Evidence from a quantitative autoradiographic study. *J Pharmacol Exp Ther* **218**:797–804.
- Unwin N (1993) Neurotransmitter action: Opening of ligand-gated ion channels. *Cell* **72**(Suppl):31–41.
- Vanhoutte PM, Humphrey PPA and Spedding M (1996) International Union of Pharmacology: XI—Recommendations for nomenclature of new receptor subtypes. *Pharmacol Rev* **48**:1–2.
- Varecka L, Wu C-H, Rötter A and Frosthalm A (1994) GABA<sub>A</sub> benzodiazepine receptor  $\alpha 6$  subunit mRNA in granule cells of the cerebellar cortex and cochlear nuclei: Expression in developing and mutant mice. *J Comp Neurol* **339**:341–352.
- Verdoorn TA (1994) Formation of heteromeric  $\gamma$ -aminobutyric acid type A receptors containing two different  $\alpha$  subunits. *Mol Pharmacol* **45**:475–480.
- Verma A and Snyder SH (1989) Peripheral type benzodiazepine receptors. *Annu Rev Pharmacol Toxicol* **29**:307–322.
- Wafford KA, Bain CJ, Quirk K, McKernan RM, Wingrove PB, Whiting PJ and Kemp JA (1994) A novel allosteric modulatory site on the GABA<sub>A</sub> receptor  $\beta$  subunit. *Neuron* **12**:775–782.
- Wafford KA, Thompson SA, Thomas D, Sikela J, Wilcox AS and Whiting PJ (1996) Functional characterization of human  $\gamma$ -aminobutyric acid<sub>A</sub> receptors containing the  $\alpha_4$  subunit. *Mol Pharmacol* **50**:670–678.
- Wafford KA, Whiting PJ and Kemp JA (1993) Differences in affinity and efficacy of benzodiazepine receptor ligands at recombinant  $\gamma$ -aminobutyric acid<sub>A</sub> receptor subtypes. *Mol Pharmacol* **43**:240–244.
- Wagstaff J, Knoll JH, Fleming J, Kirkness EF, Martin-Gallardo A, Greenberg F, Graham JM, Menninger J, Ward D and Venter JC (1991) Localization of the gene encoding the GABA<sub>A</sub> receptor  $\beta_3$  subunit to the Angelman/Prader-Willi region of human chromosome 15. *Am J Hum Genet* **49**:330–337.
- Wang TL, Guggino WB and Cutting GR (1994) A novel  $\gamma$ -aminobutyric acid receptor subunit ( $\rho$  2) cloned from human retina forms bicuculline-insensitive homooligomeric receptors in *Xenopus* oocytes. *J Neurosci* **14**:6524–6531.
- Whiting PJ, McKernan RM and Iversen LL (1990) Another mechanism for creating diversity in gamma-aminobutyrate type A receptors: RNA splicing directs expression of two forms of gamma 2 subunit, one of which contains a protein kinase C phosphorylation site. *Proc Natl Acad Sci USA* **87**:9966–9970.
- Whiting PJ, McAllister G, Vassilatis D, Bonnert TP, Heavens RP, Smith DW, Hewson L, O'Donnell R, Rigby MR, Sirinathsinghji DJS, Marshall G, Thompson SA and Wafford KA (1997) Neuronally restricted RNA splicing regulates the expression of a novel GABA<sub>A</sub> receptor subunit conferring atypical functional properties. *J Neurosci* **17**:5027–5037.
- Wilcox AS, Warrington JA, Gardiner K, Berger R, Whiting P, Altherr MR, Wasmuth JJ, Patterson D and Sikela JM (1992) Human chromosomal localization of genes encoding the  $\gamma_1$  and  $\gamma_2$  subunits of the  $\gamma$ -aminobutyric acid receptor indicates that members of this gene family are often clustered in the genome. *Proc Natl Acad Sci USA* **89**:5857–5861.
- Williamson RE and Pritchett DB (1994) Levels of benzodiazepine receptor subtypes and GABA<sub>A</sub> receptor  $\alpha$ -subunit mRNA do not correlate during development. *J Neurochem* **63**:413–418.
- Wisden W, Herb A, Wieland H, Keinänen K, Luddens H and Seeburg P (1991) Cloning, pharmacological characteristics and expression pattern of the rat GABA<sub>A</sub> receptor  $\alpha_4$  subunit. *FEBS Lett* **289**:227–230.
- Wisden W and Seeburg PH (1992) GABA<sub>A</sub> receptor channels: From subunits to functional entities. *Curr Opin Neurobiol* **2**:263–269.
- Wong G, Gu ZQ, De Costa B and Skolnick P (1993) Labelling of diazepam-sensitive and -insensitive benzodiazepine receptors with tert-butyl-8-chloro-5,6-dihydro-5-methyl-6-oxo-4H-imidazo [1,4] benzodiazepine 3-carboxylate (ZG-63). *Eur J Pharmacol* **247**:57–63.
- Wong G, Uusi-Oukari M, Hansen HC, Suzdak PD and Korpi ER (1995) Characterization of novel ligands for wild-type and natural mutant diazepam-insensitive benzodiazepine receptors. *Eur J Pharmacol* **289**:335–342.
- Woodward RM, Polenzani L and Miledi P (1993) Characterization of bicuculline/baclofen-insensitive ( $\rho$ -like)  $\gamma$ -aminobutyric acid<sub>A</sub> and  $\gamma$ -aminobutyric acid<sub>B</sub> receptor agonists and antagonists. *Mol Pharmacol* **43**:609–625.
- Yang W, Drewe JA and Lan NC (1995) Cloning and characterization of the human GABA<sub>A</sub> receptor  $\alpha_4$  subunit: Identification of a unique diazepam-insensitive binding site. *Eur J Pharmacol* **209**:319–325.
- Yasumatsu H, Morimoto Y, Yamamoto Y, Takehara S, Fukuda T, Nakao T and Setoguchi M (1994) The pharmacological properties of Y-23684, a benzodiazepine receptor partial agonist. *Br J Pharmacol* **111**:1170–1178.
- Ymer S, Draguhn A, Wisden W, Werner P, Keinänen K, Schofield PR, Sprengel R, Pritchett DB and Seeburg PH (1990) Structural and functional characterization of the  $\gamma_1$ -subunit of GABA<sub>A</sub> benzodiazepine receptors. *EMBO J* **9**:3261–3267.
- Zaman S, Harvey RJ, Barnard EA and Darlison MG (1992) Unusual effects of benzodiazepines and cyclodiene insecticides on an expressed recombinant invertebrate GABA<sub>A</sub> receptor. *FEBS Lett* **307**:351–354.
- Zeuzula J and Sieghart W (1991) Isolation of type I and type II GABA<sub>A</sub>-benzodiazepine receptors by immunoaffinity chromatography. *FEBS Lett* **284**:15–18.
- Zhang D, Pan ZH, Zhang X, Brideau AD and Lipton SA (1995) Cloning of a gamma-aminobutyric acid type C receptor subunit in rat retina with a methionine residue critical for picrotoxinin channel block. *Proc Natl Acad Sci USA* **92**:11756–11760.